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The Effects of Drug Abuse on Oral Health
Betzalel Krasnow
Betzalel Krasnow graduated in January 2018 as a Valedictorian of his class with a B.S. degree in Biology and will
be attending Touro College of Dental Medicine.

Abstract
Drug abuse, currently a national epidemic affecting millions of Americans, causes numerous health issues including increased dental disease. There are several factors which can contribute to an increase in caries and missing teeth. One of the most discussed
mechanisms is xerostomia. Drug abusers tend to have large sugar intakes which exacerbates the problems caused by xerostomia.
Drug abusers are also at risk for oral infections associated with dental decay due to their altered saliva composition. Unfortunately,
once the symptoms are present there is little that can be done to correct them and the goal of the treating dentist should be
increased dental hygiene and ongoing prevention.
Introduction
Substance abuse and misuse is a national public health crisis.
In 2015, more than 27 million people in the United States reported current illicit drug use or misuse of prescription drugs.
In addition, The National Survey on Drug Use and Health reported that over 66 million people misuse alcohol in a month.
Alcohol and drug misuse and related disorders are taking an
enormous toll on individuals, families, and society as a whole
as a result of the increased costs of healthcare associated with
these conditions.

Methods
The articles mentioned in this paper were collected and compiled using research available to the public through Google
Scholar, PubMed, and EBSCO host. Some of the articles may
be under restricted access to academic circles and was made
available to the author through the TouroLib system. Sources
were evaluated for usefulness based on publication date and
original publication source.

Commonly abused drugs
In addition to the many psychological and medical challenges
presented by drug abuse, there are also extensive oral health
problems which drug abuse causes. To further understand the
nature of the oral health issues, it is first necessary to understand what is considered a drug and the major classes of drugs
which people tend to abuse. Drugs can be defined as an exogenous chemical not necessary for normal cellular functioning that
significantly alters the function of certain cells in the body, even
when taken in relatively low doses. Endogenous neurotransmitters are not drugs, synthetic chemicals which mimic the effects
of these endogenous chemicals, however, are considered a drug.
Another stated qualification for a drug is that it is effective even
in small quantities, this is an important part of the definition, as
large quantities of any substance will alter the normal function of
cells (Carlson, 2013).
People abuse drugs for the euphoric feelings and their ability to
cause “mental detachment”.The reason why people do not abuse
antibiotics is because they do not induce these feelings.The drugs
which people abuse can be separated into two distinct categories,
central depressants and stimulants, defined by their effects on
neurotransmitters. In the world of illicit drugs, these substances
are often referred to by a “street name”. It is important for a
clinician to be familiar with not only the pharmaceutical name

of a drug but with the street name as well, since many patients
may not know the pharmaceutical name and may resort to using
street names (Rome, 2001).
Stimulants, or “Uppers”, is a class of drugs that mimic the effects of the sympathetic nervous system. The endogenous agonists of the sympathetic nervous system are the catecholamines;
epinephrine, norepinephrine, and dopamine. The catecholamines
function as both hormones and neurotransmitters. The pharmacokinetics of these drugs can affect a multitude of mechanisms,
direct activation of postsynaptic receptors, the breakdown and
reuptake of neurotransmitters, and stimulating production of
catecholamines. Stimulants include, caffeine, ephedrine, nicotine,
and cocaine.
One of the most commonly abused stimulants is methamphetamine. Methamphetamine, also known as, meth, speed,
crank, tweek, chalk, amongst other names, is a white crystalline
powder. Methamphetamine can be snorted, smoked, or injected.
The popularity of methamphetamine is in large part because of
its ease to obtain. Methamphetamine can be synthesized at home
from commonly available ingredients (Lineberry and Bostwick,
2006). The FDA approves methamphetamine hydrochloride,
sold under the name Desoxyn, to treat attention deficit disorder with hyperactivity as well as exogenous obesity, however
the FDA advises that the inherent risk of methamphetamine
must be strongly considered when prescribing it. The physical
effects of methamphetamine are systemic. They include, loss of
appetite, hyperactivity, tachycardia, bradycardia, rapid breathing,
dry mouth, excessive sweating, and bruxism. Methamphetamine
is taken recreationally to produce euphoria as well as an aphrodisiac. This article will discuss the effects of methamphetamine
on oral health. Methamphetamine causes periodontal disease as
well as rampant caries (cavities), the effect of methamphetamine
on oral health is so unique that it has been referred to as Meth
Mouth (Rommel, et. al, 2015).
The second class of drugs is depressants, or, “downers”.
Depressants, are the opposite of stimulants, they lower neurotransmission levels and depress arousal and stimulation in
the brain. The pharmacokinetics of depressants are slightly
more complicated. Neurons communicate through excitatory
synapses, one neuron excites another which excites another
neuron, and so on. If this excitatory process would happen uncontrollably, the neurons in the brain would be firing constantly,
resulting in a seizure. To prevent this from happening, there is a
class of neurons which have inhibitory effects. These neurons
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secrete GABA (gamma-aminobutyric acid) which has a postsynaptic inhibitory effect. Depressants activate the various GABA
receptors which results in an overall inhibitory effect. The most
commonly prescribed class of depressants are benzodiazepines.
Benzodiazepines are drugs which are used to reduce anxiety,
promote sleep, and reduce seizures. Valium (diazepam) and
Librium (chlordiazepoxide) are two common benzodiazepines.
Other common depressants include barbiturates, cannabis, and
alcohol (Carlson, 2013).
Opioids, the current medical terminology which refers to
both endogenous and exogenous opioid, are drug which have
the properties of both a depressant and a stimulant. Opioids
create a state of euphoria, much like a stimulant, but its physical
expression is similar to that of a depressant, i.e. slowed breathing, sedation, and hypothermia (NAABT.org). What is particularly scary about opioids is their tendency to cause respiratory
depression. Even a small dose can be lethal, when taken together
with Xanax (alprazolam), or other commonly prescribed drugs,
which also causes respiratory depression.
With the exception of alcohol, drug abuse was limited to
a small population who tended to be socially disadvantaged.
Today, drug abuse is evenly distributed across all social strata
(Friedlander and Mills, 1985). The stereotypical drug abuser is
one of low socioeconomic status, and frequently neglects both
general and oral hygiene. With the increase of abusers who do
not fit this image, the issue of drug abuse, and its effect on oral
health, has now come to the forefront.

Drug Abuse and Dental Decay
The correlation between drug abuse and severe dental decay has
long been known. A study conducted in Iran was composed of
5,900 people; 2,662 were men (45.1%), between the ages of 15
and 75. One thousand and eleven (17.1%) of those people used
opioids. The participants in the study underwent a face to face
interview with a trained practitioner, during which information
pertaining to the frequency of their drug use was obtained. In
accordance with the Diagnostic and Statistical Manual of Mental
Disorders (DMS-IV2), individuals who reported taking opioids at
least three times a week were considered addicted. After the interview a dentist performed a thorough oral exam. Dental decay
was recorded according to the DMFT index (decayed, missing,
and filled teeth) established by the World Health Organization.
Dental plaque and gum disease were also noted using the plaque
index and the community periodontal index (CPI).
For people addicted to opioids, participants had a mean number of 9.07 teeth missing, compared to a mean of 6.42 for non-addicted users.There was a mean of 9.50 decayed teeth for addicted
opioid users compared to 8.95 decayed teeth for participants not
addicted to opioid use. Similar results for the number of filled
teeth as well; 6.36 fillings for addicted participants compared to
a mean of 3.89 for non-addicted participants. Overall the DMFT
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index for addicted users had a score of 17.10 compared to 13.10
for non-addicted users (Mohammadi, et al. 2017).
The authors say that the data proves a clear increase in the
number of missing, decayed, and filled teeth, in opioid users.
There are however some shortcomings with the study.Although
other studies consider self-reporting of drug use a reliable indicator of actual drug use, there are of course people who are not
totally honest with their drug use habits. More challenging, however, is the difference in age among the participants in the trial.
The mean age of the addicted individuals was 56.01 while the
mean age of non-addicted individuals was 48.19. This difference
is statistically significant (p=0.00) considering the large sample
size. Some of the discrepancy in the DMFT index between the
addicted and non-addicted individuals can be associated with
the age difference as aging is an influence in tooth loss. The
study would have been more reliable had the mean age of the
two groups been the same or at least statistically insignificant.
A study of 571 methamphetamine users in Los Angeles
County, California was conducted and also shows a correlation
between methamphetamine use and dental decay. This study
focused exclusively on methamphetamine users and compared
their results to a study done by National Health and Nutrition
Examination Survey (NHANES). NHANES does a survey every
two years, with participants selected to be nationally representative without being selected based on risk factors or pre-existing conditions. This study was conducted to answer two questions, do methamphetamine users have a higher rate of dental
disease compared to non-users, and are different teeth affected
between methamphetamine users and non-users.
Participants in the study were selected based on stratified
sampling protocol of heavy, mild, and moderate, methamphetamine users. Intraoral exams were conducted by dentists who
were trained by the national examiner in the NHANES study. All
protocols of the study adhered to NHANES regulations so that
the two studies can have maximum comparability. Although many
variables were tested, the main one focused on was the DMFT
index. As opposed to the Iran study which relied on self-reporting of drug use alone, this study utilized urine testing to confirm
drug use. Data was also collected on sociodemographic and
behavioral variables; gender, age, ethnicity, education, history of
smoking, frequency of basic oral hygiene, and soda consumption.
Whereas the Iran study compared opioid users and non-users with little regard for sociodemographic information and the
differences it may make, this study divided the participants into
five propensity score groups, with each group having comparable sociodemographic backgrounds as the participants in the
NHANES study. Multiple statistical analysis tests; t tests, chisquare tests, and Fisher tests, were used to confirm the accuracy in comparing the data from the Los Angeles County study to
that of the NHANES study.
Of the 571 participants in the study, 19 of them were
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completely edentulous (missing teeth). A shocking number considering that mean age of the participants was only 44. Compared
to the NHANES study, methamphetamine users were forty percent less likely to have all their teeth. Methamphetamine users
were also found to have approximately four times more caries
and were twice as likely for the caries to be untreated. Close
to twenty percent more methamphetamine users had decayed,
missing, or filled teeth compared to the NHANES participants.
Methamphetamine users were also more likely to have missing
teeth when compared to the demographically similar NHANES
participants (Shetty, et.al. 2016).
Similar studies from other locales also point to an increase
in both the number of missing teeth and the number of carries
in patients addicted to drugs. A study in Queensland, Australia
studied several drugs and their role in dental decay (Reece,
2007). Another study, based in Munich, Germany also determined that there is a correlation between methamphetamine
and rampant caries (Rommel, 2015).

Xerostomia
The most common complaint methamphetamine users express
is that of “dry mouth” (Shafer, 2005). One study has 72% of
substance abusers reporting suffering from an excessively dry
mouth (Rommel, et. al., 2016). Dry mouth or xerostomia, is a
fairly common complaint with estimates ranging between 0.9%
and 64.8% of the population suffering from a form of dry mouth.
There is a lack of data on the prevalence of xerostomia leading
to such a wide range (Navazesh and Kumar, 2009). Xerostomia
is usually associated with salivary gland hypofunction.
Although saliva is ninety-eight percent water, the other two
percent contains many important substances. Included in those
substances are the electrolytes, sodium, potassium, calcium,
chloride, bicarbonate, and phosphate. Saliva also contains important enzymes needed for digestion, amylase, lingual lipase,
and kallikrein. Another important component of saliva is its antimicrobial enzymes; lysozyme, lactoperoxidase, lactoferrin, and
immunoglobulin A.
The importance of the electrolytes in saliva is their ability to
regulate and maintain the pH of the mouth. Ideally, the pH of
the mouth should be between 6.2 and 7.4. Anymore acidic and
the acid can dissolve the hard minerals which make up the teeth.
The ions present in saliva act as a buffer, keeping the pH within
that important range.
Although there have been some studies which did not find
a correlation between decreased saliva production and drug
abuse (Busfield, 1961), more recently there are others that have
reported a correlation (Heng, et al. 2008). The mean saliva production of a person is 1-2 ml/min. A stimulated salivation of less
than 0.7 ml/min is considered low. In one study, the average
methamphetamine user had an average saliva flow rate of only
0.36 ml/min (Rommel, et. al., 2016).

Saliva production is regulated by both the sympathetic and
parasympathetic nervous systems. When norepinephrine
binds to the alpha-adrenergic receptor it causes an increase
in calcium levels which results in increased saliva production.
Methamphetamine seems to activate the alpha-2-receptor
which is a salivary inhibitor in the brain (Saini, 2005).
Xerostomia is considered to be an adverse drug event of
properly prescribed opioid medication (Chapman, et. al., 2010).
Although a concrete mechanism between opioid use and xerostomia has not been found, there are several working theories
as to what may cause these symptoms. One theory is based
upon the proven correlation between opioid use and decreased
pancreas function. Perhaps there is a similar effect on the salivary glands which also are exocrine glands. Another theory is
that after opioid use, there is a clear change in color, from red
to very pale, of the oral mucosa. This change in color suggests
local vasoconstriction of the capillaries and small arterioles in
the mouth.This decreased blood flow can also inhibit saliva production (Odeh, et al. 1992).
Additionally, drug abusers also tend to go long periods with
inadequate food and drink. This leads to a generalized dehydration, resulting in decreased saliva production especially
when coupled with the hypermetabolic effects of illicit drugs
(Goodchild, et al. 2007) Another theory points to the concomitant use of antidepressants and other drugs which can also
cause xerostomia (Darke and Ross, 2000).

Sugar Intake
Regardless of any proven cause of drug abuse induced xerostomia, the mere fact that drug abusers consider their mouth to
be dry, leads to another problem. Drug abusers tend to crave
sugar and drink large amounts of non-diet soda. Mountain Dew
is a commonly reported favorite drink of methamphetamine
users and contains 31 grams of sugar, the equivalent of eight
sugar cubes, in a single eight ounce serving. When considering that that is a single serving, and one can have many cups
over the course of one day, that is an abnormally high level of
sugar consumption (Goodchild, et al. 2007). One case report
mentions a light user of methamphetamine, who would drink
1.5 liters of soda a day, that is a staggering one hundred and
ninety six grams of sugar consumed from drinks alone (Wang,
et al. 2012). As part of the Los Angeles County survey of 541
methamphetamine users, researchers obtained the number of
non-diet soda drinks they had per day. The results of the study
when compared to national averages, show a direct correlation
between non-diet soda consumption and methamphetamine
use. Although for years there was anecdotal evidence to this,
this was the first survey to confirm it from a scientific and statistical standpoint (Murphy, 2016).
Opioid users have an additional factor which increases their
sugar levels. There are three main opioid receptors in the brain;
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mu, kappa, and delta (Titsas and Ferguson 2002). Preclinical animal studies suggest that action of mu and kappa agonists at
the nucleus accumbens shell, hypothalamus, and paraventricular
nucleus is associated with a development of a preference for
sweetened food. Furthermore, eating sugar results in a down
regulation of enkephalin MRNA production which then results
in an increase in mu receptor agonism (Mysels and Sullivan,
2010). This increase in sugar consumption, especially when
coupled with hyposalivation, leads to rampant caries and subsequent tooth loss.
Methamphetamine abuse leads to hyperactivity and excessive
neuromuscular activity which causes bruxism (Rommel, et. al.,
2016). Bruxism is excessive jaw clenching and teeth grinding.
Opioid users also suffer from bruxism as there is an increase in
neurosis which results in jaw clenching and teeth grinding (Titsas
and Ferguson, 2002). Although bruxism is relatively common in
non-drug dependent adults as well, the degree of grinding and
clenching seems to be much greater in the addicted population.
Bruxism shows to be particularly damaging to drug abusers due
to the already weakened enamel from sugar consumption, poor
oral hygiene, and hyposalivation.

Oral Infections
Another problem which drug abusers face is oral candidiasis.
Opioids have been found to have an inhibitory effect on the
phagocytosis of Candida by macrophages (Titsas and Ferguson,
2002). Saliva also plays a role in preventing oral candidiasis as it
unifies the innate immune defense against Candida Albicans and
prevents its proliferation. Saliva also contains the immunoglobulin IgA which aggregates the Candida Albicans cells and then destroys them by swallowing the aggregate (Salvatori, et al. 2016).
Candida Albicans has also been found to cause pulpal inflammation, resulting in tooth loss, when the microorganism reaches
the pulp through dental caries (Baumgartner et. al. 2000).
It has been known for a long time that Streptococcus mutans
is a pathogenic organism which causes enamel loss and caries
(Loesche, 1986). Recent clinical studies have shown large numbers of Candida albicans along with Streptococcus mutans in
plaque obtained from carious lesions. Scientists were surprised
to find this as no other co-colonization between this bacteria and yeast were previously known (Carvalho et al. 2006).
Recent research shows that co-culture of Candida albicans and
Streptococcus mutans with sucrose resulted in production of
the S. mutans exoenzyme (GtfB) that bound to mannans and
β-1,3 glucans found on the fungal outer cell wall, allowing them
to survive the innate immune factors present in the mouth. In
the same study, it was shown that coinfection in rats with both
C. albicans and S. mutans increased the severity and number of
smooth-surface caries lesions by 2-fold in the presence of sucrose (Falsetta et al. 2014). It is no surprise then that drug abusers who have an increased presence of both Candida albicans
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and Streptococcus mutans as well as a large sugar intake are at
risk for severe caries.
One theory for the increase of dental disease in drug abusers
was the caustic nature of inhaled and smoked drugs (McGrath
and Chan, 2005). The Los Angeles County study, however, found
that the dental consequences of methamphetamine abuse were
more pronounced in users who injected the drug (Shetty, 2016).
With injection of the drug there should be little or no decay
if the issue was the caustic nature of the smoke. Heavy drug
abusers tend to inject the drug as it provides for a quicker and
stronger “high.” The poor health of heavy drug abusers and the
increase of the associated side effects are probably responsible
for the findings of the Los Angeles County study.

Treatment Concerns
Drug abusers will usually only visit the dentist after they stop
abusing the drug and they are suffering from severe pain. It is
therefore important that dentists be aware of previous drug
abuse to avoid prescribing a medication which may cause relapse.
Most users will not admit that they are or were users for fear of
being judged.Therefore dentists must be trained to recognize the
main signs and symptoms of drug abuse (De-Carolis, et al., 2015).
Dentists should also take notice of skin lesions which can indicate
intravenous drug use. The practitioner may decide to take the
patient’s blood pressure as a way of disguising their search for
needle tracks (Saini, et al. 2013). Dentists should not make use
of pre-written prescription forms as it can potentially be used to
obtain drugs which were not prescribed (Smit and Naidoo, 2015).
When treating patients who have a history of drug abuse, providing adequate pain relief can be challenging. Most abusers have
a tolerance to several pain medications as a result of drug abuse,
and other medications may cause relapse (Saini, 2013). Local anesthetic containing epinephrine (commonly used as a vasoconstrictor in dental surgery) must be avoided as there are known
drug interactions between epinephrine and commonly abused
drugs. The importance of this must be stressed to the patient
as it may result in cardiac dysrhythmias, cerebrovascular injury,
and even myocardial infarctions (Smit and Naidoo, 2015). Dentists
may recommend non-steroidal analgesics, for example, ibuprofen
and naproxen. Acetaminophen can be used as well (Saini, et al.
2013).

Conclusion
Drug abuse is considered an epidemic and there is a large effort
underway to inform the public of the dangers involved. Drug
abuse has serious detrimental effects on the body. Oral health
is one of the most noticeable side effects, as drug abusers are
commonly missing multiple teeth. Dentists must know how to
recognize the signs of drug abuse and can be on the forefront
of fighting this epidemic.
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Abstract
Many basic multicellular organisms possess some form of immune response to protect themselves against the invasion of foreign
objects. It was not until British scientist, Peter Medawar proposed a fundamental question that changed the way researchers
studied the maternofetal relationship. A fetus, being genetically different from its mother should be rejected by the maternal
immune system, however, it is not. Researchers have since discovered and developed several mechanisms that aim to explain how
the maternal immune system prevents fetal rejection.The formation of a mechanical barrier, general and local suppression of the
maternal immune system, and a shift in cytokine concentration during pregnancy have been suggested as reasons Forthcoming
discoveries in the field of reproductive immunology may further one’s understanding of immune regulation during pregnancy, in
addition to other applications, such as, the immune responses regarding organ transplants. Although the proposed mechanisms
mentioned above helped improve the understanding of how fetal rejection is avoided, many scientists concur that additional
research is required to adequately explain the prevention of fetal rejection.
Abbreviations:
Ab- Antibody
Ag- Antigen
APC- Antigen presenting cell
MHC- Major Histocompatibility Complex
IDO- Indoleamine 2,3-dioxy-genase
Ig- Immunoglobulin
IL-2- Interleukin 2
IFN-γ- Interferon Gamma
TNF-β- Tumor Necrosis Factor Beta

Introduction and Background
The National Vital Statistics Reports presented data from a
study conducted regarding the total number of births registered in the United States, in 2015. The results showed that
there were 3,978,497 births recorded, only 1% less than the
total number of births registered in 2014 (Martin, et al. 2017).
Many women, worldwide, have successfully given birth to babies,
which interests researchers in the field of immunology. During a
lecture in England, in 1953, a British immunologist named Peter
Medawar asked, “how does the pregnant mother contrive to
nourish within itself, for many weeks or months, a fetus that is
an antigenically foreign body (Betz, 2010)?” Since then, researchers have been asking the same question (Anonymous, 1999)?

Methods
The research discussed in this paper was compiled from various
published articles, taken from Touro’s database, including Proquest
Science, EBSCO, and PubMed to research why a mother does not
reject a genetically different fetus growing inside of her.

Discussion
A.The immune system targets foreign objects
The human body’s immune system is a complex network of
biological structures intricately designed to protect the body
against foreign objects. Foreign objects may be anything the
body does not recognize as self, which may include, bacteria,
viruses, parasites, and tumors. When a foreign object enters the
body, there is a cascade of events carried out by the body’s

immune system. First, the body must identify the foreign object
as “non-self”, destroy the pathogen, and lastly, create memory
cells to ensure that the foreign object does not attack again
(Gilley, et all. 2009).

1.Recognizing “non- self ” Objects
One of the main roles of the immune system is to recognize a
pathogen and induce a response to eradicate it. Immune system
cells such as white blood cells or leukocytes aid in carrying out
the tasks. In order to initiate any immune response, an antigen
(Ag) must be recognized by special receptors. T-Lymphocytes,
killer T cells and helper T cells, play a crucial role in the recognition of Ag. T-cells recognize foreign Ag by the presentation of
peptides by the major histocompatibility complex (MHC). The
two classes of MHC are MHC I and MHC II. Major histocompatibility complex class I generally presents an intracellular viral Ag
to cells that contain CD8+ proteins. These Ag will be destroyed
by Cytotoxic T-Lymphocytes, while MHC Class II generally
presents extracellular bacterial Ag to cells that contain CD4+
proteins.These Ag are recognized by Helper T-Lymphocytes and
will be destroyed with the help of Ab. (Joyce, 2001). CD8+ and
CD4+ are cell surface molecules that bind to their respective
MHC on an antigen-presenting cell (APC). One of the most
common cells that act as an APC are macrophages. (Miceli,
Parnes, 1991).

2.Destroying a Pathogen
After the body recognized a pathogen as “non-self,” the immune
system will try to rid the body of the foreign object. There are
two main types of pathogens that will elicit two different responses. The first type is when bacteria enter the human body;
helper T cells will release certain cytokines and chemokines.
These are certain chemicals that act as chemoattractants for
other leukocytes to aid in an inflammatory response. Secondly,
will produce Plasma cells, a derivative of lymphocytes, make antibodies (Ab) that will help destroy the pathogen. Antibodies
are a Y shape structure, consisting of glycoproteins called immunoglobulins (Ig). There are 5 main isotypes of Ig with different
roles, which include: IgG, IgE, IgM, IgA, IgD. Each Ab will bind to a
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specific antigen, comparable to the interaction with a lock and a
key (Author Unknown, 2016).
In order to help T cells produce Ab, B- lymphocytes will produce specific Ab to help destroy pathogens.Antibodies produced
by B cells will circulate the body via the bloodstream and can
bind to foreign objects. After a B-cell recognizes a pathogen, the
cell matures into a plasma cell, which produces large quantities
of Ab. Antibodies have 3 main functions in the immune system.
The first role is neutralization, which is when an Ab binds to the
surface of the pathogen, thus denying any entry into the normal
body cells. The second role is to activate other defense cells
that are in the body that can elicit an inflammatory response, for
example, phagocytes. The third role is to activate a complement
system, which attracts defense cells to the infection site and
destroys the pathogen (Author Unknown, 2016).
The second type of pathogen that will cause an immune response is infection with a virus. In this case, activated Cytotoxic
T- cells are able to directly destroy the pathogen when it displays pathogen peptides on the MHC Class 1. Cytotoxic- T cells,
also called Killer T cells release cytotoxins, such as perforin,
which creates a hole in the wall of the infected cell. This in turn
kills the cell along with the pathogen due to the loss of fluid
(Author Unknown, 2016)

B. Fetal Cells and a Mother’s Immune System
In order to better explain the interaction between fetal cells
and the mother’s immune system, one must understand what
happens after a sperm fertilizes an egg. Once an egg is fertilized,
it rapidly divides to form the blastocyst, a hollow ball of cells
comprised of two portions. One is the inner cell mass that will
become the embryo, which will develop into a fetus about eight
weeks after conception. The second is the outer layer of the
blastocyst, which will become the trophoblast. The trophoblast
will ultimately occupy the lining of the uterus, thus facilitating
embryonic implantation (Urman, Balaban 2001).

C. Immune System During Pregnancy
Based on the roles of the human’s immune system, one could
assume that a mother’s immune system would try to eliminate
a fetus. When a mother conceives a child, genetic material from
both the mother and the father are incorporated into the fetus,
however the mother’s mother’s side of the placenta is genetically different from the fetus. Therefore, the fetus inside the womb
would be considered “non-self” (Lightner, et al, 2008). Peter B.
Medawar suggested the “immunological paradox of pregnancy”
(Mor, 2007). He proposed that since the fetus is considered
“semiforeign,” there must be a conflict between the fetus and
the mother’s immune system. For over 60 years since Medawar
posed this phenomenon, there have been many attempts to
explain why a mother’s immune system does not reject a genetically different fetus.
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Accepted Hypotheses
a. Mechanical Barrier
The first hypothesis explains that the fetal tissue is unrecognizable as “nonself” by the mother’s immune cells due to a mechanical barrier (Mor, 2007). The uterus of a pregnant mother has a
mechanical barrier, consisting of synctiotrophoblasts that envelop
the fetus. This trophoblast-immune interaction includes three
stages (Fig. 1). During the first stage of attraction, the trophoblast
cells secrete chemoattractants that will signal immune cells to
migrate to the implantation site. The implantation site refers to
the area of the uterus in which the trophoblasts invade. After
attraction, the trophoblasts produce cytokines that regulate the
differentiation of immune cells. This stage is called recruitment
and/or education. Upon completion of these two steps, the response can take place. In this stage, the immune cells from stage
two respond to different signals (Swain, 2013). After completion
of all three stages, the mechanical barrier is formed. This in turn
prevents the movement of activated T cells from the periphery
to the implantation site and enables antigens that are inside the
barrier to be undetected by the mother’s immune system.

b. Suppressed Immune System During Pregnancy
Research done by David Munn and his colleagues at the Medical
College of Georgia in Augusta suggests a different hypothesis.
They discovered that macrophages, an important immune cell
involved in antigen presentation, can disable killer T-cells. This
in turn will prevent the T cells from attacking any object that is
recognized as non-self (Anonymous, 1999). In order for this to
occur, the synctiotrophoblasts in the placenta produces an enzyme known as indoleamine 2,3-dioxy-genase (IDO). The function of IDO is to destroy tryptophan, an amino acid required
by T cells to destroy a foreign object. In 1990, Andrew Mellor, a
colleague of Munn, concluded that IDO inhibits a mother’s T cell
response towards a genetically different fetus. On the contrary,
if a mother fails to produce IDO, it would cause the mother to
miscarry (Gura, 1998).
Munn and his colleagues conducted experiments in to prove
their hypothesis. They used two groups of pregnant mice; one
group had been bred to genetically identical fathers of the same
strain while the second group was bred to fathers from a genetically different strain (Gura, 1998). The experimenters then
embedded time release-capsules consisting of either 1-methyl-tryptophan, which is an IDO inhibitor, or a control substance
underneath the skin of the pregnant mice. Results showed that
only the mice carrying genetically different fetuses that had
been given the inhibitor rejected their fetuses (Anonymous,
1999) (Gura 1998). Interestingly, the embryos developed normally until inflammatory cells migrated to the implantation site
and caused hemorrhaging around the embryo. Munn proposed
“the mother is rejecting the placenta and eventually the embryo chokes off and dies” (Gura, 1998). From the data collected,
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Munn and his colleagues concluded that after implantation, an
embryo starts making connections with the mother’s blood
supply. Sequentially, synctiotrophoblasts will start producing
IDO, destroying tryptophan and suppressing the maternal immune system (Gura, 1998). However, other researchers have
reservations about this hypothesis. In Pregnancy Reconceived,
Mor argues that if the maternal immune system is suppressed, it
would be nearly impossible for a mother and its fetus to survive.
Exposure to any pathogen would be fatal (Mor, 2007).

c. Local Active Suppression in Decidua
In addition to the general suppression of a mother’s immune
system, researchers have found that an important role in the
maternofetal interaction is the local active suppression by cells
in the decidua (Chaouat, 1990). The decidua is a mucous membrane lining of the uterus during pregnancy. This lining allows
for nutrition and gas exchange before the placenta is functional
(Mizugishi, et al. 2007). Cells located in the decidua may inhibit
the production of lymphocytes thus leading to the inhibition of
the production and expression of receptors for interleukin 2 (IL2). IL-2 is a cytokine signaling molecule produced by activated T
cells and is crucial for the rejection of foreign objects in the body.
This type of suppressor cell is trophoblast independent. However,
there is another type of cell that suppresses the role of IL-2 in
the maternal immune system and these suppressor cells in the
decidua are trophoblast dependent. ¬ Both types of suppressor
cells have an effect on the production or action of IL-2.
Therefore, local active suppression aids in the prevention of
foreign objects attacking the mother’s immune system and fetal
rejection (Chaouat, 1990.)

d. Cytokine-shift Hypothesis
This hypothesis suggests that during pregnancy, the balance
of cytokines within the mother’s body shifts. This cytokine
shift causes immunological changes in the maternal immune
response (Mor, 2007). Cytokines, which are important in cell
signaling, are released by Th1 and Th2 helper cells. However,
each subgroup facilitates a different immune response. Th1 cells
secrete IL-2, Interferon gamma (IFN-γ), and Tumor necrosis
factor, Beta (TNF-β) causing a cell mediated immune response,
while Th2 cells secrete IL-4, 5, 6, 10, and 13. These are mainly involved in antibody production (Rincón et.al, 1997). Additionally,
IL secreted by Th2 cells simulate a humoral immunity and aids
in the inhibition of the production of TNF-β and IFN-γ (Kidd
2003). The production of IFN-γ, TNF-β and IL-2 are believed to
be damaging to pregnancy. In an experiment studying pregnant
mice, these cytokines were injected into the mice and caused
fetal loss (Koch and Platt, 2003). Previous research suggests that
there is a shift towards a higher production of cytokines released by Th2 during pregnancy and a diminished production of
Th1 cytokines (Hoshimoto,et al. 2000).

When a foreign object enters the body of a women who is
not pregnant, Th1 cells will secrete pro inflammatory cytokines
that will signal for a cell mediated response to occur. However,
according to the cytokine-shift hypothesis, the balance of Th1
and Th2 will go towards the secretion of cytokines by Th2, resulting in a suppressed inflammatory response (Mor, 2007).)
Many studies have been conducted in an effort to better understand the shift of Th1 to Th2 cytokine secretion during
pregnancy. In an experiment conducted by Hoshimoto, et. al.
(2009), they gathered thirty female subjects. Group A consisted
of ten women who were non-pregnant women with regular
menstrual cycles and the other 20 healthy and pregnant women.
The pregnant women were separated into two groups, B and
C according to weeks of gestation. Group B consisted of 10
pregnant women who were in their first trimester and group C
consisted of 10 women in their third trimester.The experimenters took samples of peripheral venous blood and separated the
plasma at -80°C until ready for analysis. The results of the experiment showed the correlation between the plasma levels of
sCD26 and sCD30 and pregnancy. sCD26 and sCD30 are molecules on the surface of activated Th1 and Th2 cells, respectively.
Therefore, plasma levels of sCD26 and sCD30 correlate to Th1
and Th2 responses, respectively.
sCD26 concentrations among group A were significantly
higher than group B. Furthermore, the concentration of group
B was significantly higher than group C. This indicates that the
highest concentration of Th1 cells were among those who
were not pregnant, and the lowest concentration was among
the pregnant women in their third trimester. Concentrations of
sCD30 among groups A and B did not significantly vary, however, compared to the concentration level of group C, they were
significantly higher. The researchers concluded that there was a
significant decrease in sCD26 levels among pregnant mothers
possibly due to the shift from Th1 cytokine secretion. However,
sCD30 levels did not differ between non-pregnant women and
women in their first trimester, but decreased among women
in their third trimester. This decrease may be explained by
the increase in water retention as pregnancy progresses.
Furthermore, the researchers advise for additional investigation
in order to validate the cytokine-shift hypothesis.
Many researchers agree that cytokines play a crucial
role during pregnancy. As explained in the research done by
Hoshimoto et.al, Koch and Platt mutually agree that a Th2
response is necessary for the fetus to survive in the womb.
Results from an experiment with mice showed that there was
a 20-50% rate of fetal loss due to a lack of Th2 cytokine production. Furthermore, they applied this idea to humans and suggest that irregularities with Th2 cytokine response may lead to
miscarriages. The mechanism that causes the shift between Th1
and Th2 cytokine response in pregnancy is unknown. However,
Koch and Platt propose two plausible possibilities. Firstly, there
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is a prevention of Th1 cytokine secretion that allows the Th2
response to take over or secondly; there is a specific Th2 response, which inhibits the Th1 response (Koch, Platt, 2003).

Conclusion
This paper attempted to explain the reasons why a mother
does not reject her genetically different fetus. Although it was
not until the 1950’s when Professor Medawar first posed this
question, the wealth of knowledge on this topic is rapidly expanding. However, despite the few flaws with the hypotheses,
additional research is being studied to resolve the issue.
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Abstract
Preeclampsia is a common complication of pregnancy characterized by hypertension and proteinuria. Its symptoms are well-defined, but the pathophysiology is not fully understood. This paper analyzes several of the most credible causes of this syndrome
and attempts to relate these to the known risk factors. Current preeclampsia treatments are examined, and special focus is given
to novel experimental treatments which offer hope of ending preeclampsia and eclampsia.
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Introduction
Preeclampsia is a relatively common complication of pregnancy.
Occurring in 7% of all pregnancies in the US, it is defined as an increase in blood pressure combined with proteinuria. More severe
cases of preeclampsia have the potential to advance into eclampsia,
which is preeclampsia with the addition of seizures. Preeclampsia
and eclampsia have the ability to cause lasting harm or death to
both mother and fetus, but the cause of these diseases is largely
unclear (Papadakis & McPhee, 2017).
Risk factors for preeclampsia are known. Hypertension, kidney
disease, family history, diabetes, and obesity are all linked to a higher incidence of preeclampsia. Preeclampsia is commonly called a
disease of the first pregnancy, though women who have had preeclampsia before are also at greater risk of developing it in subsequent pregnancy. Strangely enough, cigarette smoking seems to
prevent preeclampsia.There are other known risk factors as well.
Some of the pathophysiology of preeclampsia is understood.
It is believed that preeclampsia develops from poor placentation and the release of soluble fms-like tyrosine kinase 1 (sFlt1)
into the mother’s bloodstream. However, the increase in sFlt1
levels is often not distinct enough to use as a screening tool.
Additionally, the original cause of the increase is unknown.
Treatment of preeclampsia is largely based on symptoms, with
the goal being the continuation of the pregnancy for as long
as possible. Almost all symptoms disappear within 48 hours
after delivery, so it is in the mother’s best interest to give birth.
Conversely, the fetus needs more time in utero to develop. The

physician must balance the conflicting needs of the two patients
by managing the mother’s symptoms. Further understanding of
the underlying causes of preeclampsia can result in more effective treatment and better outcomes for preeclamptic women
and their children.

Methods
Peer-reviewed journal articles were obtained using Touro
College’s database and Google Scholar. The articles were critically read, analyzed, and compared. Special attention was given
to retrospective studies and reviews due to the dearth of original studies in their references. This can be attributed to the fact
that pregnant women tend to be apprehensive about joining
clinical studies.

Discussion
Symptoms of Preeclampsia
Preeclampsia is a complication of pregnancy involving hypertension and proteinuria. It cannot be prevented. Instead, pregnant
women are screened for symptoms and treated accordingly.
These symptoms usually present in the third trimester, but can
occur from 20 weeks’ gestation. It is diagnosed when a patient
presents with blood pressure of 140/90 or greater, and more
than 0.3 g of proteinuria in 24 hours. Some women also have
edema. Severe preeclampsia involves higher blood pressure
as well as thrombocytopenia, headache, and blurred vision
(Papadakis & McPhee, 2017).
Severe preeclampsia is also characterized by hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome.
This diagnosis was first made in 1982 and is currently found
in 0.2-0.8% of pregnancies. HELLP syndrome is rarely seen in
non-preeclamptic patients, though preeclampsia is about ten
times as common as HELLP. Like preeclampsia, HELLP is a syndrome, a collection of symptoms whose one underlying cause is
uncertain.The hemolysis aspect is a result of damaged endothelial cells in small blood vessels. Fibrin strands in the blood vessels cause red blood cells to become fragmented, often causing
anemia. Microangiopathy also slows hepatic portal blood flow,
damaging the liver. The same microangiopathy also exposes
tissue factor on blood vessel walls which activates coagulation
pathways. These blood clots lower platelet counts and can lead
to further complications such as uncontrolled bleeding or placental abruption (Abildgaard & Heimdal, 2013).
If preeclampsia continues, it can develop into eclampsia, which
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is defined as all of the symptoms of preeclampsia with the addition of seizures. Eclampsia is easily prevented by administration
of magnesium, so it is usually only seen in patients lacking prenatal care, or in developing countries where access to this anticonvulsant is unavailable. Hyperexcitability and extreme reflex
responses are typical signs that eclampsia may be developing
(Papadakis & McPhee, 2017; Duley, 2009).
Preeclampsia is primarily a disease of the mother, so the fetus is
not always affected. This is especially true in milder cases of preeclampsia, where the pregnancy is allowed to continue until term.
However, this is not to say that the fetus is never endangered.
Fetal growth restriction is a complication often correlated with
preeclampsia. Because of the mother’s angiopathy, blood supply to
the fetus can be reduced.This does not allow the fetus to receive
adequate nutrition, causing a low birth weight (Duley, 2009).
More seriously, preeclampsia often forces an early delivery because of the mother’s symptoms. Preterm delivery, in this case
meaning before 34 weeks’ gestation, is associated with various
complications. There is the immediate problem of insufficient
surfactant maturity in the lungs, causing the baby to go into respiratory distress upon birth. Low birth weight often causes complications later in life, including cardiovascular problems, diabetes,
and obesity. Additionally, increased risk of cerebral palsy has been
associated with children of preeclamptic mothers. Although preeclampsia primarily affects the mother, the fetus is not spared of
all effects (Papadakis & McPhee, 2017; Duley, 2009).

Causes of Preeclampsia
The causes of preeclampsia are poorly understood. Because
preeclampsia is a syndrome, a collection of symptoms which
may or may not come from one underlying cause, the pathogenesis can be different for different patients. Most people agree
that preeclampsia’s cause lies in the placenta due to the fact
that the disease disappears upon delivery. It is hypothesized
that poor placentation is a cause of preeclampsia. In normal
pregnancies, cytotrophoblasts from the placenta invade the
mother’s myometrium and increase blood supply to the fetus. In
preeclamptic placentas, insufficient invasion and remodeling of
the mother’s arteries occur. The placenta is therefore hypoxic,
and parts of it break down and release debris into maternal
circulation. This debris, containing trophoblast cells and keratin
fragments, causes the inflammatory response of preeclampsia,
microangiopathy and hypertension (Redman & Sargent, 2005).
Normal placentas release vascular endothelial growth factor
(VEGF) and placental growth factor (PlGF). Both are angiogenic
factors which allow the placenta to build an adequate vascular
network for the fetus’s development.When VEGF or PlGF binds
to a receptor on placental cell surfaces, increased vascularity is
shown. A soluble form of this receptor, soluble fms-like tyrosine
kinase-1 (sFlt1), increases in the third trimester. This receptor
floats freely in the placenta and maternal serum. When sFlt1
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binds to VEGF or PlGF, they are unable to create blood vessels,
proving sFlt1 to be antiangiogenic, and possibly the cause of
the poor placentation described above. This factor is further
increased in preeclampsia, and is found to increase even before
clinical signs of the syndrome are evident. It is believed that
excess sFlt1 can cause preeclampsia; what is unknown is how
this excess develops in the first place and what can be done to
prevent it (Redman & Sargent, 2005; Levine et al., 2004).
It is believed that decreased free VEGF and PlGF in the maternal blood supply leads to the endothelial dysfunction of preeclampsia. In the kidneys, the lack of free VEGF causes glomerular endotheliosis; constantly circulating VEGF is necessary for
renal function. The swelling of kidney cells then does not allow
for proper filtration of the blood, causing proteinuria. Exactly
how or if sFlt1 causes hypertension is unknown.
As would be expected, women with lower VEGF and PlGF levels and higher sFlt1 levels tend to have more severe symptoms
of preeclampsia and eclampsia.Additionally, when sFlt1 is administered to nonpregnant rats, they develop preeclamptic symptoms.
VEGF inhibitors or VEGF gene knockouts cause hypertension and
proteinuria in pregnant and nonpregnant rats. Cancer patients
taking VEGF-inhibitors to limit blood supply to a tumor will also
often exhibit hypertension and proteinuria, further proving the
role of sFlt1 in preeclampsia (Levine et al., 2004).
Preeclampsia is widely considered a disease of the nulliparous woman. In a Norwegian study examining data from over
700,000 births between 1967 and 1998, preeclampsia was found
in 3.9% of first pregnancies (Skjærven et al., 2002). This is compared to a 1.7% incidence for second pregnancies, and 1.8% for
third. The incongruous increase for third pregnancies is quite
small and probably a statistical artifact. It is unknown exactly
why preeclampsia is much more common in first pregnancies.
What is known is that if a mother was preeclamptic in her first
pregnancy, she is at risk for preeclampsia in later pregnancies
as well. Somehow, nulliparity seems to cause preeclampsia. This
Norwegian study claims that preeclampsia is a result of the
mother being exposed to her partner’s foreign antigens and
responding inflammatorily, causing preeclampsia. In later pregnancies by the same man, preeclampsia is less likely because
the partner’s antigens are no longer unrecognized by her body.
Giving weight to this theory, the more time that elapsed between pregnancies, the more likely the mother was to develop
preeclampsia, even if she had not previously been preeclamptic. As time passed, the immune system’s ability to recognize a
partner’s antigens decreased. Women whose second pregnancies were by different partners appear to have the same risk of
preeclampsia as nulliparous women. This supports the idea that
preeclampsia is partially caused by foreign antigens; a new partner supplies new antigens for which the mother is unprepared.
However, since women who have changed partners often have a
larger birth interval, it is very uncertain if the change in partner
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actually increases the risk for preeclampsia. Interestingly, previous miscarriage seems to reduce the risk of preeclampsia in
a later, successful pregnancy. This can also be connected to the
idea of interbirth interval, as many women who miscarry attempt to get pregnant again very soon thereafter. Nulliparity is
known to be a risk factor for preeclampsia; the reason for this is
not totally clear (Skjærven et al., 2002; Sibai et al., 1995).

Risk Factors
There are many risk factors for preeclampsia, including chronic
hypertension and kidney dysfunction, obesity, diabetes, previous
preeclamptic pregnancies, family history of the mother or father,
birth interval, age of the mother, as well as other preexisting
conditions. This paper will analyze some of the more credible
risk factors and attempt to explain the connection between
them and the disease.
Nulliparity is the most known risk factor for preeclampsia.
Whether this is due to an immune response or some other
mechanism is largely unknown. What is known is that nulliparous women are more than three times more likely to develop
preeclampsia than women who have previously had normotensive pregnancies (Duckitt & Harrington, 2005).
Women with chronic hypertension unrelated to their
pregnancy are known to have a higher risk of developing preeclampsia and eclampsia. In one population-based study, 12.1%
of preeclamptic women were found to have had hypertension
before they became pregnant (Duckitt & Harrington, 2005).This
is quite logical; high blood pressure before becoming pregnant
leads to even higher blood pressure while pregnant. Clinically,
blood pressure is used to diagnose preeclampsia. Preeclampsia
is defined as systolic blood pressure of 140 mmHg or greater
and/or diastolic blood pressure of 90 mmHg or greater, and at
least 300 mg of proteinuria over 24 hours. Blood pressure can
also be used to screen for preeclampsia. Elevated blood pressure is normal in pregnancy, but too high an elevation can be a
sign that preeclampsia will develop. In one study of nearly 3000
women, the mean systolic blood pressure at 20 weeks gestation
was 105.4 for healthy pregnancies, and 110.4 for those who
later developed preeclampsia.This is a substantial difference, but
clinically it would be difficult to gain any benefit from this statistic. Diastolic and mean blood pressure were not as useful for
prediction. Not surprisingly, women who displayed significantly
elevated blood pressure at 20 weeks were more likely to develop preeclampsia earlier than those whose blood pressure was
not as elevated. This is a more useful diagnostic tool. Systolic
blood pressure of 110 as opposed to 105 is hardly grounds to
begin watching more closely for preeclampsia. Systolic blood
pressure of 125 or 130 is (Sibai et al., 1995).
As with hypertension, kidney dysfunction before pregnancy
is likely to lead to increased kidney dysfunction while pregnant, i.e. preeclampsia. Less research has been done on kidney

dysfunction leading to preeclampsia, though. In one study of 69
pregnancies, 6.7% of women with recurring urinary tract infections developed preeclampsia, and only 2.6% of the control
group did. In other words, 2 of the 39 women with renal disease developed preeclampsia, and only 1 healthy woman did.
This is hardly enough evidence on which to build a treatment
plan. Logically, the connection between renal disease and preeclampsia seems just as strong as that between hypertension
and preeclampsia. However, not nearly as much research was
done on this juxtaposition, perhaps because of the relative rarity of renal disease in women of childbearing age (Duckitt &
Harrington, 2005).
Non-gestational diabetes greatly increases the risk of preeclampsia. A meta-analysis of multiple studies with a total
count of 56,968 women revealed that the risk of developing
preeclampsia is 3.56% greater for women who have diabetes
before pregnancy. These studies are often connected to studies
linking preeclampsia and obesity, which also approximately quadruples the risk of preeclampsia. Because women with diabetes
and high BMI often have other health problems, it is difficult
to assess exactly which of their characteristics make them
more likely to develop preeclampsia (Sibai et al., 1995; Duckitt
& Harrington, 2005). In a Saudi Arabian study of the effects of
obesity and gestational diabetes on pregnancy, it was found that
approximately 7% of women with obesity and/or gestational diabetes develop preeclampsia, compared to only 0.5% of women
with neither. The combination of the two seems to increase the
risk (Wahabi et al., 2014).
The connection between obesity and preeclampsia has been
linked to inflammation. Obesity is inflammatory, as is preeclampsia, so it stands to reason that one inflammatory state can cause
the development of an inflammatory disease. Additionally, preeclampsia often develops from hypoxic conditions in the placenta. Obesity can encourage this. Obesity is often linked with
hyperglycemia, causing hemoglobin to pick up glucose and lose
its affinity for oxygen. This does not allow enough oxygen to
reach the placenta, leading to an inflammatory response, the
release of cytokines, and subsequent endothelial dysfunction of
preeclampsia (Redman & Sargent, 2005; Schmatz et al., 2010).
Previously having preeclampsia puts a woman up to seven
times at risk for developing the disease in subsequent pregnancies when compared to women who have never had preeclampsia. It is assumed that whatever caused her to be susceptible in
the first place will also cause later incidences of preeclampsia.
A family history also puts a woman more at risk, though the
mother-in-law’s pregnancies do not seem to have much of an
effect (Sibai et al., 1995; Duckitt & Harrington, 2005).

Treatment
Treatment options for preeclampsia are largely based on symptoms. The best treatment is delivery, but immediate delivery is
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not always an option. Other treatments therefore are based on
prolonging the pregnancy for as long as possible, keeping the
mother’s health in mind (Papadakis & McPhee, 2017).
When systolic blood pressure rises above 160 mmHg, or diastolic above 110, antihypertensive drugs are administered to
bring blood pressure back down to 140/90, the threshold for
preeclampsia’s diagnosis. In severe preeclampsia, steps are taken
to ensure that the patient will not develop eclampsia. If the
mother begins to experience muscle spasms or hyperexcitability, showing that her CNS is beginning to be affected, magnesium
sulfate is administered as a relaxant. Magnesium is also given to
patients with eclampsia. Obviously, these women are monitored
for toxicity. Calcium has been suggested as an aid in preeclampsia, but no real benefits have been proven (Papadakis & McPhee,
2017; Levine et al., 2004).
Delivery is the best option for the mother, and it is the treatment of choice from 36 weeks onward. Before that point, clinicians must decide if the fetus is ready for life outside the womb.
If the fetus’s lungs are not mature enough for birth, corticosteroids are administered to the mother for 48 hours, followed
by induced delivery or cesarean. The steroids allow the fetus’s
lungs to mature more quickly. If the mother’s symptoms are
severe, such as in eclampsia, waiting for fetal lung maturation is
not necessarily an option. Delivery must then be induced to the
detriment of the fetus (Papadakis & McPhee, 2017).
Preeclampsia is a major cause of preterm delivery. Early delivery is often necessary for the mother’s sake; the child suffers.
Premature birth can result in respiratory distress, admittance to
the NICU, low birth weight, jaundice, seizures, as well as other
complications in infancy and later in life (Papadakis & McPhee,
2017). Fetal mortality is a large concern; preeclampsia is correlated with 25% of stillbirths and neonatal deaths in developing
countries (Duley, 2009).
Both aspirin and nicotine appear to reduce the risk of preeclampsia. Aspirin has antihypertensive properties, so its role in
decreasing the incidence of preeclampsia makes sense. In one
study of healthy, nulliparous women, 4.6% of those given aspirin
developed preeclampsia, compared to 6.9% of those given placebo. However, the aspirin did increase the risk of abruptio placentae, which makes the idea of treating all pregnant women with
aspirin less appealing (Sibai et al., 1993). It is recommended by
some for women at high risk for preeclampsia (Sibai et al., 1995).
Cigarette smoking is known to decrease the risk of preeclampsia, but doctors are hardly likely to begin advising smoking during pregnancy. One explanation for this phenomenon is
that nicotine appears to play a role in reducing the amount of
sFlt1 in the mother’s bloodstream. This ameliorates preeclampsia’s antiangiogenic effects and does not allow inflammation to
cause the mother to develop hypertension and proteinuria.
Even if smokers develop preeclampsia, it is usually not very severe. In a clinical trial testing aspirin’s effect, 5.9% of nonsmokers
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developed preeclampsia, compared to 2.7% of those who quit
during pregnancy, and 3.7% of those who smoked throughout.
The many negative effects of cigarette smoking on both mother
and child, though, far outweigh the small shielding from preeclampsia’s effects (Sibai et al., 1993; Jeyabalan et al., 2008).
The current treatments for preeclampsia are less than ideal,
but experimental treatments may give us some better options.
It is important to note that designing preclinical and clinical trials for these treatments can be quite difficult. Animal models are
often less than ideal as these animals may have very different
placentas than humans. Many of these trials involve animals that
do not ever develop preeclampsia. Scientists instead create situations to mimic preeclampsia’s symptoms in vivo. Moving on to
a clinical trial in humans will only occur after extensive testing.
Nobody wants a repeat of the thalidomide disaster, so advancement in pregnancy treatment moves slowly (Sibley, 2017).
In a 2016 study of 28 rats, apelin was used to successfully
ameliorate symptoms of preeclampsia. Apelin is a peptide found
in the cardiovascular system. Among other effects, it reduces
blood pressure in atherosclerosis and encourages angiogenesis. In this experiment, half of the rats served as control (N
group), and half of these were given apelin (N+APLN group),
an angiogenic factor naturally present in mammalian placentas.
Preeclamptic placentas usually have lower apelin than normal.
The acceptable rat model of preeclampsia was used on half the
rats (PE and PE+APLN); uterine arteries were clamped to prevent adequate blood flow to the placenta, leading to the release
of cytokines and debris causing hypertension and proteinuria.
Half of these rats were then treated with apelin. The rats given
apelin had lower blood pressure and proteinuria than the preeclamptic control, but not as low as the healthy rats. Apelin also
increased fetal survival rate and birth weight. One hundred percent of N and N+APLN embryos survived, 25% of PE survived,
and 50% of PE+APLN survived. Considering that fetal survival
rate for humans with preeclampsia is much better than 25%,
it is reasonable to believe that apelin would cause even better
survival rates in humans. The effect on preeclampsia’s maternal
symptoms are also likely to carry over. However, as apelin was
only tested on 8 preeclamptic rats, and because rat placentas
differ greatly from human ones, much more research must be
done before apelin is the drug of choice for preeclampsia (Sibley,
2017; Wang et al., 2017).
Researchers have also recommended mediating the effect of
sFlt1 on the mother’s body by somehow increasing the levels of
VEGF in the placenta. One method of doing so is by injecting
adenovirus vectors for VEGF into the placenta. This was done
in sheep and guinea pig models, as well as in human placentas
in vitro. The increase in VEGF levels mediates the inactivation
of VEGF by sFlt1, resulting in an approximately normal quantity of angiogenic factors. This appears to create normal uterine
blood flow and cure preeclampsia. The virus vector also does
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not appear to cross the placenta and cause other complications.
This treatment is extremely promising and is moving towards
clinical trial in Europe (Sibley, 2017).

Conclusion
Preeclampsia is a major obstetrical complication still common
in the developed world. Its causes are not fully understood, but
are largely believed to develop from hypoxic conditions of the
placenta.The placenta releases inflammatory factors, causing hypertension and proteinuria for the mother, as well as other side
effects. Fetal effects include growth restriction and the negative
effects related to premature birth. Risk factors are well-known
yet poorly understood, and prophylactic treatments such as
aspirin are available. Treatment for preeclampsia and eclampsia
now mainly revolve around symptoms, but experiments are underway which will hopefully lead to a greater understanding and
more effective treatment for this syndrome.
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Abstract
Takotsubo Cardiomyopathy (TTC) is a temporary heart-wall motion abnormality with the clinical presentation of a myocardial
infarction. Found predominantly in postmenopausal women, TTC most often appears with apical ballooning and mid-ventricle
hypokinesis. Often induced by an emotional or physical stress,TTC is reversible and excluded as a diagnosis in patients with acute
plaque rupture and obstructive coronary disease. The transient nature and positive prognosis of this cardiomyopathy leaves a
dilemma as to what precipitates it.This paper explores the theories of the pathogenesis of TTC including coronary artery spasm,
microvascular dysfunction, and catecholamine excess. A thorough analysis of the pathogenesis was conducted using online databases.The coronary artery spasm theory involves an occlusion of a blood vessel caused by a sudden vasoconstriction of a coronary
artery. This condition was confirmed in some patients with TTC using provocative testing, but failure to induce a coronary artery
spasm in many patients led to its dismissal as a primary pathogenic mechanism. It is however a significant occurrence in patients
with TTC and cannot be dismissed entirely.The microvascular dysfunction theory is challenged in the limited and underdeveloped
methods of testing for its presence. However, using the corrected Thrombolysis in Myocardial Infarction frame count method to
evaluate the flow of contrast in coronary arteries, researchers were able to indicate diffuse impaired coronary microcirculation in
the myocardium. The theory involving catecholamines is based on the catecholamine surge that many patients experience with
emotional or physical stressors.The stressor leads to excitation of the postsynaptic sympathetic neuron and the adrenal medulla,
stimulating an influx of norepinephrine and epinephrine and the resulting hypokinesis of the apical portion of the left ventricle.
Further research focused on this theory discovered the protective nature of estrogen against the catecholamine surge, explaining
the prevalence of TTC in post-menopausal women. Genetic research perpetuates this theory by presenting predisposed genetic
factors that prevent TTC. Analysis of the three theories found the catecholamine theory to be the most probable mechanism
behind TTC, but further research is necessary to confirm TTC pathogenesis.
Introduction
Background
The cardiovascular system encompasses the extensive network
that supplies the body with the nutrients and oxygen it needs to
function. At the center of this complex system, the heart serves
as an anatomical pump to push the blood out of its chambers and
throughout the body. The sinoatrial node stimulates the cardiac
muscle to contract periodically, and its normal rhythm can be
measured on an electrocardiogram (ECG). In the presence of
cardiac dysfunction, this test can indicate specific abnormalities
in the sinus rhythm. The left ventricle is the heart’s main pumping chamber, and a weakening or abnormality in its function can
produce severe repercussions. There are multiple causes of left
ventricular dysfunction. In the case of Takotsubo cardiomyopathy
(TTC), sources like coronary artery spasm, microvascular dysfunction, and catecholamine excess are suspected to contribute
to its pathogenesis (Komamura, et al. 2014). These theories are
evaluated and debated in many recent studies that seek to discover the likely origin and development of TTC.
The syndrome was first described in 1990 by a Japanese cardiologist which prompted its name, Takotsubo cardiomyopathy
(Sato, et al. 1990). Translated from Japanese to “octopus trap”,
takotsubo describes the shape of the left ventricle during systole in many patients suffering from TTC. Resembling its namesake’s rounded bottom and narrow neck, TTC most commonly
appears with apical ballooning and mid-ventricle hypokinesis.
TTC is also known as stress-induced cardiomyopathy, ampulla cardiomyopathy, transient left ventricular apical ballooning,
and broken heart syndrome. The latter title indicates the likely
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Figure 1. Left ventriculogram exhibiting Takotsubo. A: end-diastolic
phase; B: end-systolic phase. Here, the apex shows akinesis with
visible hypercontraction of the basal portion. C:Takotsubo, an
octopus trap. (Akashi, et al. 2008)
presence of an emotional or physical trigger that precipitates
the condition. Researchers found stressors such as the sudden
death of a loved one, anxiety over a family member’s congenital disorders, and vigorous excitation to be responsible for the
onset of TTC in some of their subjects (Tsuchihashi, et al. 2001).
There are instances where no physical or emotional stressor is
indicated and the trigger is unknown (Gianni, et al. 2006).

Epidemiology
This specific cardiomyopathy is a relatively new diagnosis with
the number of published cases growing in the past 20 years.The
condition occurs predominantly in postmenopausal women
which lends to one of the pathogenic theories of TTC regarding
lack of estrogen and its effects on catecholamine levels in the
body (Komamura, et al. 2014). A study found a 6.3-fold higher incidence of the condition in women than in men, differing
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from the usual male dominance in coronary artery diseases
(Tsuchihashi, et al. 2001). A systematic review of 14 studies
found that 88.8% of TTC patients were women, leaving significant room for a pathogenic mechanism that can explain the
specific epidemiology of TTC.

Clinical Manifestations
Takotsubo cardiomyopathy’s most common symptomatic presentation includes severe chest pain and dyspnea, resembling the
symptoms of an acute myocardial infarction (Komamura, et al.
2014). Where myocardial infarctions are generally preceded by
atherosclerosis, plaque buildup in arteries, TTC is excluded as a
diagnosis in patients that present with artery blockage or a history of obstructive coronary artery disease. A study found 90% of
its subjects without preceding conditions admitted to chest pain
or discomfort with the onset of TTC (Tsuchihashi, et al. 2001).
Serum level indication using cardiac biomarkers found creatine
kinase and troponin T to be elevated in many cases, indicating a
heart muscle abnormality. Creatine kinase expressed in cardiac
muscle is used to assay damage to the heart in various cardiac
conditions. In TTC, there is a slight elevation from the normal
22-198 IU/l (Tsuchihashi, et al. 2001).Troponin T, a cardiac protein
released when the heart muscle is damaged, is found to be similarly elevated (Gianni, et al. 2006). In 86.5% of patients with TTC,
left ventricular ejection fraction was reduced to 40.7±11.2% from
its normal 55% or higher. Studies also note increased left ventricular end-diastolic pressure in 93% of patients with this condition
(Templin, et al. 2015) (Tsuchihashi, et al. 2001).

Diagnosis
According to Heart Failure Association’s diagnostic criteria, patients need to fulfill the following specifications for their condition to be classified as TTC.The first is the presence of a wall motion abnormality involving the dyskinesis, hypokinesis or akenesis
of the left ventricle mid segments. This includes the ballooning of
the apex as it fails to contract. Echocardiograms or cardiac ventriculography can be used to identify this cardiomyopathy (Abe, et
al. 2003). In addition, TTC is indicated only in the absence of obstructive coronary disease and acute plaque rupture and can be
determined using angiographic images of the coronary arteries.
This exclusion differentiates TTC from a myocardial infarction, a
heart attack, which is caused by acute plaque ruptures and presents with similar symptoms. The third criteria for the diagnosis
includes the appearance of new, reversible sinus rhythm changes
on the patient’s ECG. Most commonly, the condition appears with
ST-segment elevation and T wave inversion (Gianni, et al. 2006).
Another criterion is the significant elevation of serum natriuretic
peptide (BNP or NT-proBNP), a blood indicator of heart failure.
Bloodwork to assess cardiac enzyme levels like Troponin T is also
used in the diagnosis of TTC. Perhaps the most important aspect of diagnosing a patient with TTC is the transient nature of

the condition. Essentially, the patient should recover full cardiac
function within a week of the acute episode. If a patient does not
recover full systolic function within 12 weeks, a different diagnosis
should be considered (Komamura, et al. 2014).
The Mayo Clinic’s diagnostic criteria includes the absence of
pheochromocytoma, a hormone releasing tumor of the adrenal
glands. If a patient presented with additional symptoms such as
sweating, tachycardia, and headaches, pheochromocytoma was
suspected (Reeder, Prasad, 2017). However, the updated conclusive criteria released by the Heart Failure Association, allows for
pheochromocytoma as a trigger for TTC in the event that it precipitates a catecholamine storm (Ansari, El-Battrawy, 2017). Mayo
Clinic also addresses the exclusion of myocarditis, inflammation
of the myocardium, as part of its diagnostic criteria. Myocarditis
involves slower recovery than TTC and can be excluded with the
absence of scarring and myocardial inflammation on cardiovascular magnetic resonance imaging (MRI). MRI also confirms the
reversible wall motion abnormalities and the quantification of the
ventricular function in a patient with suspected TTC.

Management
Due to its transient nature, TTC can often be managed by
addressing and alleviating the physical or emotional stressors
that triggered the onset of the cardiomyopathy. Although there
are not any conclusive treatments, treatments generally administered for heart failure such as beta blockers, ACE inhibitors,
and diuretics, are often administered as supportive care for
TTC patients. A possible treatment specified for older women
is estrogen administration. This was found to be beneficial in an
animal model of TTC, though clinical trials have not yet been
performed. The general prognosis of TTC is positive, but complications have occurred in many patients ranging from cardiogenic shock and left ventricular outflow tract obstruction, to
severe systolic dysfunction. Diagnosis and management of these
conditions is imperative to reduce the fatalities attributed to
TTC (De Backer, et al. 2014).

Methods
The research in this paper was compiled using the online databases, Pubmed and UpToDate, and through Touro’s online library
system for access to databases Proquest and Ebsco. Keywords
Takotsubo cardiomyopathy and Broken heart syndrome were
used in the initial research of this paper. Careful analysis of
the gathered material prompted further research using sources cited in articles on this topic. Both peer reviewed articles
and clinical studies were analyzed to evaluate the hypothesized
pathogenic mechanisms of Takotsubo cardiomyopathy.

Discussion
When evaluating the pathogenesis of TTC, researchers are
faced with various differentiating origins and pathways that TTC
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can develop from. A worldwide investigation of patients with
TTC has led to several possible theories of the cardiomyopathy
including a coronary artery spasm, catecholamine excess, and
microvascular dysfunction. While studies have produced results
that support all three theories, there is still a significant amount
of research required to determine the definitive pathogenic
mechanism of TTC.

Coronary Artery Spasm
The heart is a recipient of its own labor in its utilization of
its blood supply from the coronary arteries. In order for the
heart muscle to function, the correct amount of blood supply
in regular increments must be delivered through these arteries.
Many have hypothesized that an abnormality in this cycle is the
source of TTC in the form of a coronary artery spasm. A coronary artery spasm is a temporary contracting of the wall of the
artery that constricts blood flow and leads to decreased blood
supply to the heart muscle. The occlusion or near occlusion of
the vessel can cause decreased muscle movement in the heart
chambers that depend on the regular blood supply from the
coronary arteries.
Studies performed on patients with TTC support this theory. In one case study, a 79-year-old man was admitted to a
hospital presenting with three consecutive days of chest pain.
Echocardiography showed hyperkineses in the basal wall and
akenesis in the apex of the left ventricle. In order to locate the
source of the cardiomyopathy, doctors performed provocative
testing using ergonovine, a muscle contractant. The diagnostic
screening test induced a right coronary artery spasm and resulted in ECG changes with increased ST segment elevation
in leads II, III, and aVF. The patient’s normal left ventricle wall
motion was restored one week later, and he was subsequently
diagnosed with TTC with a pathogenesis attributed to a coronary artery spasm (Misumi, et al. 2010).
Although there are many cases of patients with TTC experiencing induced coronary artery spasm from provocative testing
using either ergonovine or acetylcholine, there are more that
have not. Many patients with TTC did not present with increased
susceptibility to ergonovine or acetylcholine in provocative
testing, and according to reports, only 30% of patients presented characteristics of a vasospasm with testing (Komamura, et
al. 2014). This research leaves a substantial gap in the coronary
artery spasm theory (Madias, 2014). Nonetheless, the presence
of coronary vasospasm in some TTC patients cannot be ignored
and this theory has therefore not been completely dismissed.

Microvascular Dysfunction
Another theory explored as a pathogenic mechanism of TTC
is microvascular dysfunction. The primary obstacle in exploring this mechanism is the limited technology available to evaluate microvascular function. One study was performed using
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the Thrombolysis In Myocardial Infarction (TIMI) frame count
technique, a quantitative, continuous variable that assesses flow
changes by counting the cineframes it takes for contrast to
reach coronary landmarks. Researchers evaluated the flow of
the left anterior descending artery, left circumflex artery, and
the right coronary artery in order to suggest diffuse impaired
coronary microcirculation in the myocardium. In 23 of the 24
patients studied, there was a slowdown in coronary microcirculation noted (Fazio, et al. 2010). A more recent assessment
pointed out that the akinesis in the left ventricles of those patients was too large of an area to be attributed to the dysfunctional microvessels’ supply (Vitale, et al. 2016). A corrected TIMI
frame count was performed and found that the flow was slower
in the left anterior descending artery and the researchers suggested this being the source of akinesis in the apex while the
base is relatively spared in TTC (Khalid, et al. 2015). However,
the combined studies do not find microvascular dysfunction to
be the primary source of TTC, but it is likely to play a role in
the etiopathogenesis.

Catecholamine Theory
The catecholamine theory is perhaps the most well developed
and significant theory of TTC. Many patients are noted to have
grossly elevated plasma catecholamine levels, measuring at two
to three times greater than in patients with myocardial infarctions and twenty times higher than normal adults (Zeb, et al.
2011). These elevations were noted of both adrenomedullary
and sympathoneurally-derived catecholamines. The adrenal
medulla releases epinephrine and norepinephrine after stress,
which activates preganglionic sympathetic nerves. In addition,
the peripheral sympathetic nerves release norepinephrine, both
of which contribute to the β-adrenergic pathway. The common
emotional or physical stressor in patients is tightly connected
with this theory in its influx of catecholamines. Researchers
concluded that the stressor induced hyperactivity of the sympathetic nervous system and prompted the release of catecholamines into the patient’s blood stream (Tarkin, et al. 2008).
The apex of the left ventricle has higher adrenoceptor density than the base, presenting location specific evidence for the
cardiomyopathy. The influx of catecholamines, both epinephrine
and norepinephrine, are directed to the β-adrenergic pathway. This pathway is specifically located at the apex of the left
ventricle, likely to produce the heart’s fight or flight response
of hypercontraction of the cardiomyocytes. The β-adrenergic
receptors in the cell membranes bind to the catecholamines
which ignites this response. The overstimulation of Gs (activator) through β2-coupling due to catecholamines can cause
apoptosis of the myocytes. The process therefore switches to
Gi (inhibitor) to protect the myocytes from further damage.
This causes a decrease in contraction and results in the hypokinesis of the apex of the left ventricle. There is serum evidence
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of slight necrosis caused by the excess catecholamine in the
minimally elevated troponin levels in patients with TTC. Studies
showed that a signaling pathway known to exhibit anti-apoptosis functions, phosphatidyl inositol 3-kinase protien kinase
B, presented increased activity. This may be the source of the
quick recovery of the myocytes. In addition to this, the transient
nature of this condition can be attributed to the inverse switch
from Gi to Gs resulting in the expeditious recovery of systolic
function in patients (Nef, et al. 2009).
Another theory on the rapid recovery of the myocytes is related to stem cells.A study using in vivo and in vitro cardiomyocytes
and cardiac stem cells found that the cardiac stem cells were
resistant to neurohumoral overstimulation. Researchers injected male Wistar rats with isoproterenol and noted left ventricle
dysfunction in the subjects. The left ventricular function began
to improve on day three post isoproterenol stimulation. β-adrenoreceptor hyperactivity from the catecholamine stimulation
leads to PKA-mediated hyperphosphorylation of the ryadonine
receptor 2, a calcium channel that mediates the release of Ca2+
from the sarcoplasmic reticulum to the cytoplasm. This hyperphosphorylation causes Ca2+ leakage which, in turn, produces
myocyte damage. The cardiac stem cells have low levels of β-adrenergic receptors and do not express ryadonine receptor 2.This
explains the resistance cardiac stem cells possess to the catecholamine overstimulation and the regeneration of cardiomyocytes
that restore normal left ventricle function (Ellison, et al. 2007).
There is research that suggests specifically local release of
catecholamines are at play in TTC. This is based on the findings in a study performed on blood samples from both the
aortic root and coronary sinus of patients with the condition.
Catecholamine concentration was found to be higher in the
coronary sinus signaling excessive local catecholamine release
from the heart (Kume, et al. 2008).
Besides for emotional stressors, catecholamine excess resulting in TTC is precipitated by other factors like acute brain injury
or treatment of respiratory distress. A study done on patients
with subarachnoid hemorrhage reports of eight patients developing TTC as a result of a brain aneurysm rupture. Researchers
theorize that at the time of the event, patients experience a
catecholamine surge which can mediate cardiopulmonary dysfunction (Franco, et al. 2010). A case report presenting a patient
with acute asthma exacerbation who was treated with β-2 agonist nebulization and intravenous aminophylline. After fourteen
hours of treatment she complained of shortness of breath and
pain in her jaw. Testing showed classic TTC with ST segment
elevation, T wave inversion, and left ventricular apical akinesia.
The treatment was immediately stopped and replaced with ipratropium nebulization and intravenous corticosteroids. After
48 hours the echocardiogram revealed full recovery. Additional
studies report that methylxanthines, the structural classification of aminophylline, stimulate the release of catecholamines

from the adrenal medulla and of norepinephrine from cardiac
β-adrenergic nerve endings (Khwaja, Tai, 2016). Another study
reports a similar case with a patient treated with nebulized
adrenaline to manage an airway obstruction. Like the previous
case study, this patient developed TTC post adrenaline treatment (Keshtkar, et al. 2016).These reports present a medication
administration that possibly caused a catecholamine surge suspected to have induced the patients’ TTC.
While the catecholamine theory is the most developed and
scientifically supported mechanism of TTC, not all patients are
found to have elevated catecholamine levels, prompting continued investigation into a definitive pathogenesis of the condition
(Tarkin, et al. 2008).

Low Estrogen Levels
The occurrence of TTC specifically in post-menopausal women
prompted the investigation of estrogen deficiency as a predisposing factor. One study demonstrated increased estrogen
serum levels in rats weakened cardiac changes in response to
immobilization stress. P44/p42 mitogen-activated protein kinase
was activated by the immobilization stress along with the upregulation of immediate early genes in the myocardium. Immediate
early genes are activated in response to cellular stimuli at the
transcription level. The study theorizes that estrogen attenuated this process and inhibited the activation of the sympathetic
nervous system by decreasing the formulation of immediate
early genes in both the brain and heart (Ueyama, 2004). In a
study published by this author more recently, it was determined
that, in response to immobilization stress, ovariectomized rats
that received estradiol did not experience a significant decrease
in left ventricular contraction. The ovariectomized exposed to
stress sans estradiol treatment did, however, experience percentage contraction reduction (Ueyama, et al. 2003). An evaluation of women with TTC found that majority of the patients
were post-menopausal and had not undergone estrogen replacement therapy. Researchers postulated that lack of estrogen
replacement therapy may predispose women to TTC (Kuo, et al.
2010). Combined, these studies propose that post-menopausal
women, who experience a deficiency of estrogen, lack a protective barrier against the development of TTC.

Genetic Predisposition and the Catecholamine
Theory
With analysis, the catecholamine theory appears problematic
because not all patients experience this cardiac dysfunction
with an emotional or physical stressor that may cause a catecholamine surge. Genetic research introduced new theories
that address this dilemma.
The apparent exclusiveness of patients who develop TTC suggests that the general population possesses a molecular mechanism that protects their cardiomyocytes from a catecholamine
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surge and prevents necrosis. Bcl2-associated athanogene 3
(BAG3) is a constituent of an autophagy pathway and one that
allows for the degradation of intracellular components. A study
found that it is expressed in response to various stressors and
is therefore theorized to promote stress resistance. The ablation of BAG3 in mice resulted in lethal cardiomyopathy shortly
postnatal. The study found that BAG3 single-nucleotide polymorphisms resulted in TTC. It introduced a novel post-transcriptional pathway that, in response to epinephrine treatment,
leads to BAG3 expression. Micro-RNAs are fundamental in
their role as repressors of messenger RNAs’ translation. The
study describes miR-371a-5p, a pathway that binds miRNA to
3’-untranslated region (3’-UTR) of the BAG3 gene. Epinephrine
induces miR-371a-5p which leads to BAG3 upregulation in
cardiomyocytes. However, this protective mechanism is lost in
patients who possess a single nucleotide variant involving the
3’-UTR in the BAG3 gene which alters the miR-371a-5p pathway and eliminates its binding. This genetic variant of BAG3 is
found in many patients with TTC and could explain the cardiac
dysfunction post catecholamine (D’avenia, et al. 2015).
Further research into the catecholamine mechanism produced an underlying theory involving another genetic role in
TTC. The study concluded that genetic susceptibility involving
β-adrenergic signaling increased the risk of toxicity induced by
catecholamines in TTC.
Researchers utilized technology involving the reprogramming
of somatic cells into induced pluripotent stem cells (iPSC) to
produce this conclusion. Reprogramming somatic cells of these
patients allowed for differentiation into cardiomyocytes that
could be experimented on.
The study involved healthy donors for controls and patients
with TTC. The somatic cells of the Takotsubo patients were
reprogrammed and expanded into high quality iPSC clones.
Using Wnt modulation and metabolic selection, cells were then
differentiated into cardiomyocytes (CMs). After three months,
the iPSC-CMs were subjected to isoprenaline or epinephrine
in order to replicate the catecholamine stimulation suspected
to be experienced in patients with TTC. After analysis, studies
showed that the catecholamine excess in the TTC iPSC-CMs
was apparent in the increased expression of NR4A1, a cardiac
stress-related gene. Compared to the control iPSC-CMs, the
TTC iPSC-CMs recorded much greater expression of NR4A1
post subjection to catecholamines. Three weeks after catecholamine administration, there was a reversal in changes to the
NR4A1 expression.
The researchers proceeded to investigate β-adrenergic signaling using the TTC iPSC-CMs.They measured cAMP levels and
PKA activation by phosphorylation and found increased levels
in both compared to the control iPSC-CMs after catecholamine
treatment. In addition, extracellular signal-regulated kinase
was phosphorylated maximally in the TTC iPSC-CMs after
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epinephrine or isoprenaline treatment where the controls were
significantly reduced in comparison. Increased lipid accumulation was also noted in catecholamine treated TTC iPSC-CMs.
Researchers examined the electrical activity of catecholamine
treated iPSC-CMs from patients with TTC and found that more
than half were silenced under certain isoprenaline concentrations where only some of the controls were. For those that
were not silenced, beating frequency was significantly increased
in the TTC iPSC-CMs in comparison to the control subjects.
The changes to the electrical activity was reversed following
washout of the isoprenaline after 24 hours.
Additionally, the study found that engineered heart muscles
using the TTC iPSC-CMs presented an impaired force of contraction. Muscles also presented a higher sensitivity compared
to control subjects to isoprenaline-stimulated inotropy, an altering of the force of muscle contractions. Further investigation
into the genetic makeup of the patients with TTC found variants
in some patients’ genes that are key regulators of cardiac function. These findings may contribute to the hypothesis of a predisposition to TTC, specifically involving catecholamine toxicity
(Borchert, et al. 2017).

Conclusion
The pathogenesis of TTC is an evolving phenomenon with developing theories.While coronary artery spasm is found in some
patients with TTC, the majority failed to experience induced
coronary artery spasm with provocative testing. Microvascular
dysfunction is a challenge to evaluate, but it has been found
to be a contributing factor in many patients with TTC, though
it is likely not the primary cause. Of the three theories presented, the catecholamine excess theory, supported by genetic
research, and the estrogen deficiency theory is the most well
developed pathogenic mechanism. In order to understand this
cardiomyopathy in its entirety and to produce an appropriate
treatment, more research is required involving integration of
the cardiovascular, central neural, autonomic, and endocrine systems in their response to stress, and the genetic predisposition
to TTC.
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Abstract
Alzheimer’s disease, the most common form of dementia, is a neurodegenerative disease that causes progressive memory loss
and severe cognitive impairment with time. As the sixth leading cause of death in the United States, Alzheimer’s disease kills more
people than breast cancer and prostate cancer combined, and there are over five million Americans suffering from Alzheimer’s disease today. A diagnosis of probable Alzheimer’s disease is typically given after rigorous neurological and psychological examination,
neuroimaging, and cognitive testing, although the diagnosis cannot be confirmed unless a postmortem examination finds specific
pathological lesions in the brain. The lack of proper diagnostic technique often leads to patients being diagnosed after years of
the disease’s progression, at which point there is already significant neurological damage. Biomarkers for Alzheimer’s disease are
therefore crucial to accurately monitor the disease’s progression and eventually determine the effectiveness of certain therapies.
There are countless studies being performed to discover the different biomarker possibilities for detecting Alzheimer’s disease
in its preclinical stage. Constructed on multiple original scientific research articles, this paper focuses on two such approaches
toward preclinical Alzheimer’s disease detection, specifically focusing on blood-based biomarkers. These detection methods have
been developed based on the two pathological characteristics of the disease, beta-amyloid plaques and neurofibrillary tangles
in the brain that lead to cerebral atrophy. The ADAM10 protease can be used as an Alzheimer’s disease biomarker by having
reduced levels in patients with the disease, lending to the hypothesis that its reduction leads to the formation of beta-amyloid
plaques. Using plasma-based tests to measure inflammatory-related responses such as cytokines and plasma signal proteins
to neurofibrillary tangles is another effective way in detecting preclinical Alzheimer’s disease. These biomarker possibilities show
promising opportunities to detect Alzheimer’s disease before or as soon as symptoms appear, thus enabling patients to receive
optimal care and treatment.
Introduction
According to the 2011 Criteria and Guidelines for Alzheimer’s
disease developed by the National Institute of Health and the
Alzheimer’s Association, there are three stages of Alzheimer’s
disease. In the first stage, preclinical Alzheimer’s disease, patients
exhibit no symptoms of memory loss or changes in behavior,
but begin to form progressive pathological characteristics of the
disease in the brain, cerebrospinal fluid, and blood. The second
stage, mild cognitive impairment, or MCI, due to Alzheimer’s
disease indicates noticeable changes in behavior and cognition
that do not affect everyday life function and activities. The final
stage is dementia due to Alzheimer’s disease. This is the stage
in which a person exhibits distinct memory loss and cognitive
decline that severely impairs everyday function (www.alz.org).
Although there are already measurable pathological changes
in the brain, cerebrospinal fluid, and blood during the preclinical
stage of Alzheimer’s disease, the changes are rarely detected
or tested for due to the lack of symptoms. While preclinical
Alzheimer’s is considered the first stage of the disease, the 2011
criteria and guidelines for Alzheimer’s disease do not list diagnostic criteria that can be used in diagnosing it, causing the typical Alzheimer’s disease patient to be first diagnosed after years
of the disease’s progression, and only after symptoms appear.
In the past two decades, there has been a huge effort to develop disease-modifying drugs to slow or stop the progression of
Alzheimer’s disease. These treatments are predicted to be most
effective in the preclinical and early mild cognitive impairment
stages. However, because most patients partaking in clinical trials
are already in advanced stages of the disease, many of these trials
have failed. Therefore, specific, easily-identifiable and accessible
biomarkers are crucial for diagnosing patients in the preclinical

stage so that their fitness for disease-modifying treatments can
be determined, and the effectiveness of such treatments can be
accurately monitored (www.alz.org). Understanding specific biomarkers would also lend patients more time to plan for their future and would give them opportunity to be involved in decisions
involving their home care and legal matters while their cognition
is still intact (Gomez Ravetti, Moscato, 2008).
Current detection mechanisms of Alzheimer’s disease include
brain imaging and cerebrospinal fluid testing. These methods,
however, are expensive and invasive, and are not easily accessible to large portions of the population (O’Bryant et al., 2011).
Additionally, these methods are inconclusive and are usually
only performed once the disease has reached the mild cognitive impairment or dementia stage and has already progressed
significantly.
Researchers are therefore in search of conclusive biomarkers that can be used in routine screenings and detection of
preclinical Alzheimer’s disease (Berg, 2008). Peripheral bloodbased biomarkers are ideal for Alzheimer’s disease screening,
as they can be easily accessed via routine venipuncture, which
is cost-effective, noninvasive, and available to majority of the
population (O’Bryant et al., 2011). This paper explores several
blood-based biomarker possibilities that can be used as routine
screenings for preclinical or early-onset Alzheimer’s disease.

Alzheimer’s Disease Pathology
Although the exact pathological cause of Alzheimer’s disease is
still unknown, there are two major pathological characteristics
that researchers have pinpointed to indicate the disease and its
progression. These characteristics are excessive beta-amyloid
peptide plaques and phosphorylated tau protein deposition in
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the brain. Through different mechanisms, these characteristics
both cause neuronal death and eventual atrophy that spreads
throughout the brain (Manzine et al., 2013).
In a normal, nonamyloidogenic pathway, amyloid precursor
protein, or APP, an enzyme embedded in the cell membrane of
neurons, is cleaved by alpha-secretase and releases a fragment
called aAPP. aAPP is a large and insoluble molecule, and is believed to have a protective effect on the neural cells it occupies.
aAPPs protect the neurons of the hippocampus against excitotoxicity, A beta toxicity, and glucose deprivation (Furukawa et al.,
1996), and enhance learning and memory function. In patients
with Alzheimer’s disease, there is a decrease in APP processing
via a-secretases (Manzine et. al., 2013). Instead, APP is cleaved
by beta-secretase, followed by gamma-secretase cleavage. Betaamyloid, the fragment produced by this pathway, is shorter than
aAPP, and when beta-amyloid fragments aggregate, they become
insoluble, forming beta-amyloid plaques. These plaques interfere with inter-neuronal communication, causing information
transfer at synapses to fail, eventually leading to neuronal death
(Cummings et al., 1996).
The second pathological characteristic of Alzheimer’s disease
is neurofibrillary tangles caused by abnormal tau protein deposition in the brain. In normal neurons, the tau protein attaches to
microtubules and stabilizes the important internal structures of
the cell by acting as a firm, scaffolding-like structure. Nutrients
are carried throughout this structure, and the tau protein is
essential for normal cell function and nutrient transport. In
patients with Alzheimer’s disease, however, the tau protein is
modified and behaves differently.Tau protein separates from the
microtubules in neurons of patients with Alzheimer’s disease,
causing the structure to fall apart. Strands of tau combine and
form tangles inside the neuron, disabling the transport system
and eventually destroying the cell (Ingelsson et al., 2004).
The accumulation of both beta amyloid plaque and

neurofibrillary tangles leads to cell death. In patients with
Alzheimer’s disease, the abundance of cell death causes the brain
to shrink in size and many important functions, such as memory,
to fail. Atrophy begins in the lateral entorhinal cortex, which together with the hippocampus plays an integral role in long-term
memory storage. Over time, the brain atrophy spreads to other
areas of the cerebral cortex, specifically to the parietal cortex,
the region of the brain associated with navigation and spatial
orientation (Liu et al., 2013), leading to severe cognitive decline.
Researchers are still unsure of the direct causes of beta-amyloid plaque accumulation and neurofibrillary tangle formation.
They have, however, pinpointed these characteristics as the
cause of cerebral atrophy and cognitive decline in patients with
Alzheimer’s disease. It is therefore useful to utilize these known
pathological markers of Alzheimer’s disease as the basis for biomarker research, as they are present not only in the mild cognitive impairment and severe Alzheimer’s disease stages, but begin
to form in the preclinical stage, prior to the onset of cognitive
symptoms (www.alz.org).

Methods
Research was done by studying original research articles and
scientific papers found on the Touro College online library.
Specific scientific databases such as Proquest and EBSCO were
perused, and additional information was obtained by analyzing
articles found.

Discussion:
Current Detection of Alzheimer’s Disease
Progression
Today, when there is concern for possible Alzheimer’s disease,
there is no definitive step to reach a diagnosis. Instead, a series
of steps must be taken to ultimately lead to a probable diagnosis
of the disease. Even then, it is only when neurofibrillary tangles

Figure 1: MRI scans of the brains of (i) cognitively normal (CN) patient, (ii) patient with amnesic mild cognitive impairment, and (iii) patient
with Alzheimer’s disease (Vemuri, Jack, 2010).
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(NFTs) in neurons, amyloid plaques, and synapse or neuronal
loss and atrophy are found upon postmortem examination of
the brain that Alzheimer’s disease can be fully confirmed (Berti
et al., 2010).
To reach a probable diagnosis of Alzheimer’s Disease, a mini
mental state exam, or MMSE, is first performed, in which the
patient is asked to fulfill certain tasks and answer a variety of
questions ranging from recalling the date and time to repeating words or sentences and copying drawings and shapes. A
gross score is assigned, and a score ranking of “cognitively impaired” will cause a doctor to send a patient for further testing
(O’Bryant et al., 2008).
Blood tests will be done to rule out other causes of dementia, such as abnormal thyroid function or vitamin B-12 levels
(Agarwal et al., 2008). The patient may then be referred to a
neurologist or sent for brain imaging to detect more specific
Alzheimer’s disease pathological markers or other causes of
cognitive impairment by looking for blood accumulation, brain
tumors, strokes, and change in brain size.
While brain imaging such as magnetic resonance imaging
(MRI) and positron emission topography (PET) scans are currently used on patients in the mild cognitive impairment or
late Alzheimer’s dementia stage, there is still much uncertainty
regarding the use of such imaging techniques in detecting the
disease in its preclinical stage. As seen in figure 1, MRI imaging
shows clear cerebral atrophy in patients with mild cognitive impairment and Alzheimer’s disease when compared to patients
with normal cognition (Vemuri, Jack, 2010). Several studies have
shown that MRI detection of atrophy of the medial temporal
lobes (MTL), the brain region responsible for language and longterm memory, can be an indication of early AD and predicts
conversion to dementia (Rusinek et. al., 2003). Additionally,
Fluoro-2-deoxy-D-glucose (FDG) PET scanning has played the
leading neuroimaging role in the early detection of Alzheimer’s
disease by using estimates of cerebral metabolic rate of glucose (CMRglc), an indication of synaptic density and function.
Patients with Alzheimer’s disease will exhibit CMRglc reductions that are visible on FDG-PET scans, which can even be
detected before the onset of Alzheimer’s symptoms (Berti et
al., 2010). However, FDG-PET and MRI scans are limited as they
lack disease specificity; other dementias exhibit reductions in
CMRglc, as well, and there can be other causes of brain atrophy
detected on an MRI (Wollman, Prohovnik, 2003).
Currently, cerebrospinal fluid (CSF) levels of tau protein and
beta-amyloid plaques are the most reliable and widespread protein biomarkers used for Alzheimer’s disease detection. This is
because cerebrospinal fluid interacts directly with extracellular
brain space and can therefore be used as an accurate marker for pathological changes in the brain (Hampel et al., 2012).
However, obtaining cerebrospinal fluid requires a lumbar puncture, or “spinal tap”, a procedure that is expensive, painful, and

time-consuming, and usually needs to be performed in a hospital setting.Testing CSF is therefore not a practical way to screen
for preclinical Alzheimer’s disease.

Genetic Risk Factors of Alzheimer’s Disease
Although environmental factors such as diet, exercise, and education play a role in the development of Alzheimer’s disease,
twin studies strongly suggest that genetics is the major factor
in its development (Gatz et. al., 2006). While many genes have
been suggested as genetic risk factors, only one, the ε4 allele
of the apolipoprotein E, or APOE, gene has been confirmed to
directly correlate to Alzheimer’s disease development (Corder
et. al., 1993).
APOE, a glycoprotein composed of 299 amino acids, functions
as a ligand, combining with lipids to form lipoproteins. APOE is
essential for cholesterol homeostasis throughout the body, and
is the principal cholesterol carrier in the brain (Puglielli et al.
2003).
Every person inherits one copy of the APOE gene from each
parent. The APOE gene has three common single nucleotide
polymorphisms (SNPs) leading to three common isoforms of
APOE: Apoε2, Apoε3, and Apoε4. The most common form of
APOE is ε3, with about 60 percent of the U.S. population inheriting one ε3 gene from each parent. Only about 20 to 30
percent of the U.S. population carries one or two copies of the
ε4 gene, and 10 to 20 percent of the population has one or two
copies of ε2. Despite these alleles differing in only one or two
amino acids, they have drastically different functions and cause
stark differences in the genotype (Raber et al. 2004).
Numerous studies have established that the Apoε3 form neither increases or decreases the risk of developing Alzheimer’s
disease, and that the Apoε2 form may decrease the risk of
developing the disease. The Apoε4 allele, however, is a strong
genetic risk factor for the development of Alzheimer’s disease
(Corder et al., 1993). Compared to people who possess no ε4
allele, people who are heterozygous for the ε4 allele exhibit a
2-3-fold increase in developing Alzheimer’s disease, and people
who are homozygous for the ε4 allele exhibit a 12-fold increase
in developing the disease (Bertram et al., 2009).
Yet despite the strong correlation between patients with
the Apoε4 allele and the development of Alzheimer’s disease,
the mechanism of how Apoε4 causes an increase in ABdeposition is still not fully understood (Holtzman et al., 2012).
Furthermore, inheriting the ε4 allele does not guarantee that
someone will develop the disease. The ε4 allele had a significantly weaker effect in some ethnic groups, such as African
Americans and Hispanics (Farrer et al., 1997), suggesting that
there are other environmental and genetic factors involved in
the onset of Alzheimer’s disease, and that the predisposition to
developing Alzheimer’s disease cannot be determined based on
this gene alone.
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Inflammatory Responses Associated with
Alzheimer’s Disease
As with any other disease, upon sensing abnormal neuronal degeneration caused by Alzheimer’s disease, the body launches an
immune response (Cagnin et al., 2001). When neurofibrillary
tangles begin to form from abnormal tau proteins, astrocytes
and microglia, usually inactive in brain tissue, are activated as
part of the initial response (Leung et al., 2013). When activated,
microglia become phagocytes and secrete many inflammatory
molecules such as cytokines and chemokines, growth factors,
complement molecules and adhesion molecules.
Several inflammatory agents have been specifically associated
with amyloid deposits, including IL-1, IL-6, a1-antichymotrypsin
(ACT), tumor necrosis factor-a (TNF-a), and transforming growth
factor (TGF-b) (Mcgeer et al., 2006). When tested in blood plasma, these inflammatory agents showed a positive correlation
with beta-amyloid peptide found in cerebrospinal fluid (Sun et
al., 2003).
Another study was done comparing cytokine expression in
blood plasma to neuropsychological testing and neuroimaging
indicating Alzheimer’s disease progression. Twenty-seven cytokines and chemokines (chemical messengers that cells release
as an immune response) were tested. The study found that five
cytokines and chemokines, IL-6, TNF-a, IL- 1ra, IL-10, and IL-13,
were inversely related to ventricular volume, whole brain volume,
or entorhinal cortex volume in Alzheimer’s disease. That is, the
greater the immune response to the disease, the smaller the brain
volume, or the further along the disease progression. There was
also an increase in the level of two cytokines, IL-10 and IFN- γ,
when tracked in patients between visits (Leung et. al., 2013).
Aside from acting as an immune response to the atrophy of
brain cells, the inflammatory response itself may also be contributing to brain atrophy. According to the amyloid cascade-inflammatory hypothesis, researchers postulate that Alzheimer’s disease
is caused by the inflammatory response to beta-amyloid deposits
and is later intensified by tau protein tangles. As the disease progresses, so does the inflammatory response, and it may be for this
reason that multiple attempts at developing disease-modifying
drugs have failed, as they fail to take the inflammatory response
into account. In this strain, possible therapies dealing with anti-inflammatory agents may show promise for developing successful
disease-modifying drugs (McGeer et al., 2013).
In a highly-publicized study, it was hypothesized that the pathological processes related to Alzheimer’s disease in the body would
trigger an immune response with specific changes in certain signal
proteins in the blood. A longitudinal study was done in which
patients were tested at the initial diagnosis of Alzheimer’s disease
with mild cognitive impairment, and were then followed up with
two to six years later. Using an algorithm called PAM (partition
around medoids), eighteen of the one hundred and twenty proteins tested were identified as Alzheimer’s disease predictors,
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with a 95% positive agreement and 83% negative agreement with
the clinical diagnosis (Ray et al., 2007).
These results showed promising statistics that warranted
additional study. The PAM algorithm was then used to predict
Alzheimer’s disease progression in twenty-two patients with
mild cognitive impairment. The prediction of twenty of the
twenty-two patients to develop Alzheimer’s disease was proven
correct when the patients were followed up with two to five
years later (Ray et. al., 2007). This highly specific plasma biomarker test can therefore be used to predict Alzheimer’s disease years before a clinical diagnosis would typically be made or
even before any symptoms appear.
A further study found that of the original nineteen predictor
proteins found by Ray et al., just five proteins could be used with
96% accuracy to detect preclinical Alzheimer’s disease. Using less
proteins caused less errors in prediction, and higher biomarker
specificity and accuracy (Gomez Ravetti, Moscato, 2008).
Immune responses to beta-amyloid deposition and neurofibrillary tangles, including activation of microglia and astrocytes to
release cytokines and chemokines, can be used as an index of
Alzheimer’s disease progression (Leung et. al., 2013). Additionally,
the use of specific signal proteins can be used to accurately
predict development of Alzheimer’s disease (Ray et. al., 2007).
Treatments aimed at dealing with these inflammatory responses
may also prove to be effective although more research is needed
to prove that hypothesis (McGeer, McGeer, 2013).

ADAM10 as a Biomarker
Efforts have been made to find biomarkers relating to the pathogenic mechanism of abnormal beta-amyloid aggregation causing
the formation of amyloid plaques. The products of the ectodomain shedding process, in which amyloid precursor protein
(APP) is cleaved by a-secretase into its soluble counterparts, can
be used as detection mechanisms of preclinical Alzheimer’s disease by methods similar to those used in measuring the immune
response (Pruessmeyer, Ludwig, 2009).
In the amyloidogenic pathway, after APP is cleaved by β-secretase, also called β-site APP-cleaving enzyme 1 (BACE1), it is then
cleaved by a γ-secretase, leading to the release of the AB fragment. BACE1 competes with the a-secretase for cleavage of the
APP substrate, so that an increase in BACE1 activity causes a
decrease in a-secretase activity, and vice versa (Vassar, 2013).
The identity of the a-secretase acting in the amyloid precursor
protein cleavage process has never been confirmed. However, in
three studies done, three members of the ADAM (A Disintegin
And Metalloproteinase) family, ADAM9, ADAM10, and ADAM17,
were suggested as possible a-secretases as their overexpression
in cells or mice led to an increase in APP cleavage (Koike et al,
1999; Lammich et al, 1999; Slack et al, 2001). To further pinpoint a single protease as the predominant a-secretase, knockout methods were used on the three ADAM metalloproteases.
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Only ADAM 10 was found to completely suppress a-secretase
cleavage of APP when knocked out. ADAM10, therefore, can be
used as a measure of a-secretase cleavage and its reduction can
be used as a biomarker to detect preclinical Alzheimer’s disease
(Kuhn et al., 2013).
In patients with Alzheimer’s disease, platelet levels of
ADAM10 were reduced. A study was done to determine whether ADAM10 could act as an a-secretase and whether obtaining
measurements of ADAM10 from platelets in blood plasma was
an accurate measurement of ADAM10 levels in the brain. When
compared to levels in cerebral spinal fluid, ADAM10 levels in
platelets were similar. This was done because platelets present
the highest levels of APP among the peripheral tissues (Colciaghi
et al., 2002).
A study was done of two groups of Brazilian elderly people to compare ADAM10 protein levels in participants with
Alzheimer’s disease versus non-Alzheimer’s disease participants.
By studying the platelet levels of ADAM10 as the only statistically significant factor to increase probability of Alzheimer’s
disease, it was found that ADAM10 levels were significantly
reduced in patients with Alzheimer’s disease versus patients
without it. The ADAM10 levels were also stage dependent; the
further the disease had progressed, the lower the ADAM10 levels were, indicating a decrease in a-secretase cleavage of APP
(Manzine et. al., 2013).

Conclusion
While many ethical concerns can be raised regarding the detrimental psychological effect of a preclinical Alzheimer’s disease
diagnosis, most patients do not react with a negative emotional response. On the contrary, an Alzheimer’s diagnosis often
comes as a relief to patients and their families by delivering a
cause for a patient’s cognitive decline (Carpenter et al., 2008).
Through the implementation of blood-based biomarkers,
there is promise for easy detection of preclinical Alzheimer’s
disease. A combination of testing levels of a-secretases like
ADAM10 and specific cytokine and chemokine inflammatory
markers can help lead to a definitive preclinical Alzheimer’s
disease diagnosis. By using a combination of the above testing
methods, Alzheimer’s disease will be able to be definitively diagnosed before symptoms appear, giving patients time to discuss
therapies and make certain decisions on their own. However,
these testing methods must still be regarded with caution as
many of them have not been tested on a vast enough population to be considered fool-proof. With further and more widespread research on the above-mentioned biomarker possibilities, there is promise for early and even preclinical detection of
Alzheimer’s disease. Easy and early detection will not only help
patients struggling with unknown causes of cognitive decline,
but will lend to more reliable research for possible drugs to help
cure this prevalent disease.
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Abstract
This paper explores the many mechanisms of how stress influences ovulation. For ovulation to occur, there needs to be a series
of hormones released in a specific order, and in a specific amount.This paper will discuss the various type of stress a person can
experience, and which specific reproductive hormone each different type of stress disrupts. This paper will also bring proof as to
how each hormone is disturbed, and by which mechanism it is disrupted.There has not been one main mechanism that has been
found thus far, therefore, it is important to take into consideration the various routes that stress can take to disturb ovulation.
Understanding the various mechanisms is important in finding a way to treat women with menstrual or ovulatory dysfunction.
Introduction
Stress plays an important role in the daily life of a healthy person
Stress can elicit biological and emotional responses which may
affect the female’s hormones, leading to change in the menstrual
cycle, and ovulation. Ovulation is the release of an oocyte from
the ovary. For ovulation to occur, a sequence of events must happen. The hypothalamus will secrete gonadotropin releasing hormone (GnRH), which stimulates the adenohypophysis to secrete
both follicle stimulating hormone (FSH) and luteinizing hormone
(LH). The levels and timing of these secretions is controlled by
GnRH, and other factors such as inhibin and activin (Hawkins,
Matzuk, 2008). The gonadotropins then stimulate the ovary to
produce the steroid hormones estrogen or progesterone, as well
as other peptides. Adequate presence of FSH stimulates the follicles in the ovary to grow even more and become competent
to develop into an antral follicle. When it is exposed to LH, it
produces estrogens from androgenic precursors. The concomitant increase in FSH on the follicular cell results in more binding
of FSH and greater amount of estrogen secretion, resulting in a
very high estrogen environment. Once high estrogen levels are
triggered, a message is sent to the anterior pituitary to induce the
LH surge, which leads to ovulation, when it picks a dominant follicle (Hawkins, Matzuk 2008).These mechanisms occur in a normal,
healthy functioning female with normal hormone levels. However,
when a female is exposed to stress, whether it is physical or mental, her hormones may not be at normal levels, thus her menstrual
cycle and her ovulation mechanism may be disrupted. This paper
will explore the effects of stress on mechanism in ovulation, and
specifically, which hormones it disrupts when a female is exposed
to a variety of different types of stress.

Method
The research obtained about the mechanism of how stress
affects ovulation was collected from a variety of sources. The
majority of the articles were collected using Touro’s library to
access databases such as Proquest, Pubmed, and many more.
Other articles were also found through google scholar. After
reviewing and studying many articles on the topic, there was
adequate evidence to answer the research question.

The Impact of General Stress on The
Reproductive System
There is a direct biological relationship between stress and the reproductive system, where stress activates a part of the body called
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the HPA Axis- the Hypothalamic-Pituitary-Adrenal axis, which is
the central stress response system.When a person is under stress,
the HPA axis is activated, and there are increased levels of cortisol
and corticotropin-releasing hormone.The cortisol and corticotropin releasing hormone has the ability to suppress the normal levels
of the reproductive hormones, which can potentially lead to abnormal ovulation, anovulation and amenorrhea (Biller, et al 1990).This
paper will explore exactly which hormones the HPA axis acts upon
in order to interfere with ovulation.
When there is a presence of adequate estrogen levels and
there is stress-induced activation of the HPA axis, a significantly
higher amount of LH is released. They found that the increase in
LH was most probably associated with the increase in adrenal
progesterone, which should feed back negatively on the gonadotrops in the pituitary to reduce LH that accompanies the release
of cortisol in response to stress. It was also discovered that progesterone can stimulate LH secretion by acting directly on the
pituitary (Couzinet, et al. 1992). Because of the stimulation of
the LH secretion, this may provoke a premature LH surge and
thereby interfere with proper follicular maturation and ovulation.
Furthermore, elevated LH concentrations at different stages of
the menstrual cycle may have conflicting effects on the maturing
follicle and on the developing oocyte and may result in early pregnancy loss, due to the egg not implanting properly.
There are many studies and research articles that support
the observation of a rise in the LH after stress. It was also
found that one of the major causes of decreased fertility is the
occurrence of premature LH surges. Although there are many
research articles, there are only a few clinical studies in humans that support our observation of a rise in LH after stress.
The Puder study suggested that one of the major causes of
decreased fertility of unstimulated cycles is the occurrence of
premature LH surges (Puder et al. 2000). These premature LH
surges, are usually a response to stress. When there is a premature LH surge, the follicle may not be ready, and ovulation will
not occur. Injecting endotoxin, a mild inflammatory stress into
his subjects revealed that those who received the highest dose
of endotoxin exhibited decreased LH levels. Generally, for an
LH surge to happen, there needs to be a high estrogen environment They found that, although the subjects may have been in
a low estrogen state when the endotoxin was administered, it
lead to a significant stimulation of the LH levels. Thus, according
to the Puder study, stress can bring on ovulation, although it
may not be at the right time of the cycle. Additionally, one of the
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potential negative effects of poorly timed increase in LH may
be premature luteinization. It could thus be speculated that the
main general mechanism by which stress affects ovulation is by
causing an increase in LH, or premature LH surges.

The Impact of Stress on The Reproductive
System as it is Exposed to Physical Stress
One of the many types of stress that a person can be exposed
to is physical stress, such as exercise. Over the past decade,
women have become much more physically active. Physical stress
affects 6-79% of females, with the severity varying on the different type of athletic activities More specifically, the mechanism
by which exercise-associated abnormalities of the reproductive
system generally stem from disruption at the hypothalamic level
(Warren, Perlroth 2001).. The amenorrheic abnormalities within
the general female population and within the population of females that were involved in sports were studied and found that
the percentage with amenorrheic dysfunction was substantially
higher in females that engaged in athletic activity (Constantini,
Warren, 1994). The main mechanism by which stress affects the
menstrual cycle and ovulation generally originates in the dysfunction of the hypothalamus and the disturbance of the GnRH pulse
generator. However, the specific mechanisms are different based
on the different type of athletic discipline. The percentage with
irregularities varied with different types of sports or exercises.
Additionally, experiments showed that exercise coupled with caloric restrictions severely affected the LH suppression, which negatively affected ovulation. However, the experiment also showed
that exercise alone did not affect the LH rhythm (Loucks, 2000).
The mechanism by which exercise, and the caloric restrictions
affected the menstrual cycle and ovulation, was through the hormone, Leptin. The hormone leptin is a protein product of the
obesity gene, and is an independent regulator of metabolic rate,
and may be found to be a significant mediator of reproductive
function. Multiple studies have shown that menstruation does not
occur in women with low leptin levels, and thus they are unable
to ovulate. (Laughlin & Yen 1997). However, these studies just
prove to us how exercise coupled with unhealthy eating affects
the LH rhythm. But how does exercise alone affect ovulation?

The B-endorphins and Catecholamines Effects
Generally, when women exercise, it has been shown that there
is an increase in the levels of B-endorphins and catecholamines.
When there are increased levels of B-endorphins and catechol
estrogens, studies have shown that the body responds with decreased levels of luteinizing hormone. However, Catecholamines
have been found to regulate the luteinizing hormone (Russell
et al, 1984). When Russell et al studied regularly menstruating
active members of a swim club, he found the following results
consistent with the above-mentioned mechanisms. They found
that the swimmers that were most active, had higher estrogen

levels. They had an increase in their catecholamines, and specifically in their levels of norepinephrine, which plays a role in
the hypothalamus to regulate hormone release.When there are
high levels of norepinephrine, the release of LH was significantly
increased. Thus, the increased release of LH in these athletes
disrupted many of their menstrual cycles and caused delayed
ovulation or anovulation (Russell et al., 1984).
The B-endorphin hypothesis was also confirmed in this
study, where they found a rapid rise in plasma B-endorphins
and B-lipotropins in competitively training athletes. As it was
mentioned previously, B-endorphins cause a decrease in the
luteinizing hormone. Additionally, the catecholamine increase
that the athletes experienced, inhibited the breakdown of
B-endorphins by blocking the enzyme that is needed to break it
down. B-endorphin was shown to block ovulation through the
mechanism of morphine sulfate. Pang et al 1977 showed that
morphine suppresses the preovulatory release of luteinizing
hormone, thus it blocked ovulation from occurring. However,
they also discovered that naloxone hydrochloride which is the
opiate antagonist, reverses the effect. Additionally, this can also
be seen by the fact that if women are chronically exposed to
heroin or methadone, they had a decrease in their gonadotropin
release and the complete absence of the luteal phase, and thus
they did not ovulate.
Norepinephrine has a great influence on the LH release hormone in the hypothalamus.As mentioned above, catecholamines
actually regulate the Luteinizing Hormone, and assure that it
is released at the proper time and with the proper amounts.
However, Russell et al. found in their study that the B-endorphins
which are released by athletes, actually suppresses norepinephrine and it cannot have its usual influences on the LH release
hormone from the hypothalamus. Additionally, in order for the
LH hormone to be released from the hypothalamus, it needs to
be promoted by naloxone, a synthetic drug, which blocks the
B-endorphins. It needs to block the B-endorphins, because as
it was mentioned before, the B-endorphins caused a decrease
in the LH, and blocked ovulation. Naloxone was discovered to
help with menstrual cycle and ovulation regulation, through an
experiment with athletes. They found that when a single dose
of naloxone was given to runners, they responded with a pulsatile LH surge. Thus, B-endorphin suppression of LH can be
overcome by giving naloxone to athletes with excessive beta
endorphins (Russell et al. 1984).

Intense Physical Activity and Ovulatory
Dysfunction
There was a high correlation that was found between women
who experienced intense physical activity and ovulatory dysfunction. It was found, regarding heavy runners, that only 50%
of runners ovulated during a test month compared with 83%
of controls. Fortunately, it was also shown that the ovulatory
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dysfunction was only at the time of the intense physical activity,
and once there was a less intense exercise schedule, their regular ovulation schedule returned (Gudmundsdottir et al, 2009).
In addition to the blockage of the LH surge by B-endorphin,
there is a common mechanism of ovulatory dysfunction which
is called Hypogonadotropic Hypogonadism. Hypogonadotropic
Hypogonadism is characterized by the failure of the pituitary
gland to produce LH and Fsh, which play the key role in ovulation. The most common cause of this is excessive exercise
(Fairley,Taylor 2003).Thus, women who exercise excessively are
likely to develop this dysfunction, and without the production
of LH and FSH, ovulation will not be able to occur. Additionally,
women who exercise excessively can develop amenorrhoea
because of a physiological reduction in the hypothalamic production of the gonadotropin releasing hormone. GnRH is also
an imperative factor in ovulation, and if there is not enough
GnRH being produced in the body, normal ovulation will not
occur. This is characterized by the fact that the GnRH hormone
regulates the timing and secretion of LH and FSH. If there is
not enough GnRH being produced, it cannot regulate these
hormones, and thus there will be a disturbance in the normal
ovulation mechanism.

Moderate Physical Activity and Ovulatory
Dysfunction
Furthermore, there was additional evidence found which revealed another mechanism of ovulatory dysfunction in healthy
women. The study was done by examining a group of healthy,
moderately exercising women. Before this study, it was thought
that the effects of exercise at the level of the GnRH pulsator
was due to the changes in LH Pulsatility (Loucks et al. 1989).
They found that like LH, alterations in FSH secretion can also
significantly impact ovarian function by altering folliculogenesis.
Usually, there is an elevation of FSH during the luteal-follicular
transition, then a decline usually happens after ovulation, during
the late follicular and early luteal phases. This study found that
the usual rise in FSH is blunted in exercising women that have a
luteal phase deficiency.This was the first report of an abnormality in the monthly pattern of FSH excretion in women (DeSouza,
Miller et al. 1998). Thus, the above study provides us with an
additional mechanism of how ovulation is disrupted through
exercise. The rise of FSH during the luteal-follicular transition
is very important for the LH surge that comes shortly after. If
there is no rise in FSH, there will not be enough LH produced,
and ovulation will not occur.
It was also found in the study done by Souza, Miller et al.
that there was a progressive suppression of estradiol excretion
during the follicular phase. A delay in the estradiol excretion will
probably follow a delay in the growth of the follicles, and thus
a delay in follicular dominance and ovulation. The data in this
study was very much consistent with the data in the previous
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studies in this paper. It supports the concept that in exercising
women, both the luteal phase progesterone excretion and early
follicular phase estrogen excretion decrease proportionally
(Souza, Miller et al. 1998).
On the contrary to what was found in the study done by
Souza, a study done by Jurkowski et al 1981 found opposite
results.They studied the effects of exercise on the reproductive
hormones, and what exercise had an effect on in the various
stages of the menstrual cycle and ovulation. They studied nine
women, and they found in all the women that when there was
an increase in the intensity of the exercise, it affected the response of both the estradiol and the progesterone. They found
that intense exercise increased the estradiol during both the
follicular and luteal phases, although Souza found the opposite.
In the luteal phase the progesterone also was increased, however, in the follicular phase they were lower. The low levels of
estrogen can be a cause of anovulation, and the high levels of
estrogen can also affect ovulation; there needs to be the right
amounts in order for ovulation to occur.

Sporadic Anovulation in Physical Activity
Although there is adequate evidence and many studies done to
prove that physical activity affects ovulation, not all studies seem
to have the same results. In a research study done by Ahrens,
et al 2014 other evidence was found. They studied 259 healthy
premenopausal, regularly menstruating women. Their focus was
to see the changes in their hormones as they were physically
active as well as to see if they had sporadic anovulation. It was
found in their study that the women with higher physical activity did have some sporadic anovulation, but nothing that was statistically significant. However, they did find that women that had
a more moderate physical activity routine, instead of an intense
physical activity routine, did have a lower risk of anovulation.
This study may not support or agree with all the previous
studies, but that does not discredit the studies that have been
done in the past. There may have been limitations on this study
that led to inaccurate results, and thus there may have been
sporadic anovulation that was overlooked.This could have been
due to the fact that the study was done based on the hormones
present in the women that was used to predict if there was anovulation. If the study was done with ultrasound technology this
would have given us more accurate results. Therefore, although
this study did not find a mechanism that ovulation was affected
by physical activity; there is adequate evidence from previous
articles that support the hypothesis that there are mechanisms
by which ovulation is affected by physical activity.

The Impact of Stress on The Reproductive
System as It Is Exposed to Emotional Stress
There is another type of stress which can critically affect a person’s body and hormones, and that is emotional stress. Anxiety

By What Mechanism Does Stress Affect Ovulation?

is a type of stress that is characterized by feelings of worry,
anxiety or fear, and in many cases, it can strongly interfere
and disrupt a person’s daily life. Not only does anxiety affect
a person on levels which are obvious and can be seen, but it
also can affect a person on a biological level. When a person
is under stress and has anxiety, their hypothalamus releases
Corticotropin Releasing Hormone (CRH) as a response to the
stress that they are experiencing.
Many studies, including one by Chen proved that the
Corticotropin releasing hormone inhibits GnRH secretion
(Chen et al. 1992). Additionally, corticotropin releasing hormone is found in many female reproductive organs; the ovaries, endometrial glands, trophoblasts etc. One mechanism by
which stress can affect ovulation was found in an experiment
done on women in-vitro. In a study done by Calogero et al, they
also found that CRH interfered with reproductive and ovarian
function by suppressing the HPG axis to release GNRH and it
affected the pulsality of the release of LH. This mechanism was
also found and is consistent with the study done by Loucks.
However, Calogero also discovered that CRH interfered directly at the gonadal level. Calogero studied many female rats and
found that CRH inhibits FSH stimulated estrogen production,
by decreasing the sensitivity of the rats to FSH. It was also
found that CRH exerts an inhibitory effect on the formation of
steroids (Calogero et al. 1996).This finding suggests that ovarian
CRH has anti-reproductive actions that might be related to earlier ovarian failure which was observed in women with high anxiety and stress. Through their experiments they hypothesized
and proved that this was through CRH inhibiting the production
of FSH, thus leading to anovulation. If there is not an adequate
release of FSH, the follicles will not be able to grow, there won’t
be a high estrogen environment and thus there will not be a LH
surge, which will lead to anovulation. Thus, CRH may also be
the major cause of anovulatory, or ovulatory dysfunction.

Three Levels Where Stress Can Influence Sexual
Functions
It is known that stress-related hormones can influence sexual
functions at all three levels of the HPG axis; in the brain which
will inhibit GnRH secretion, in the pituitary to interfere with
GnRH induced LH release, and in the gonads to alter the stimulatory effects of gonadotropins on sex steroid secretion (Rivier,
Rivest 1991).
It was hypothesized that when CRF is released during stress,
it causes the GnRH hormone to be disrupted because of the
short distance between CRF and GnRH secreting neurons. This
is believed to be the main mechanism where stress inhibited reproductive functions, because of the direct anatomical connections between CRF axon terminals and dendrites of GnRH secreting neurons (Maclusky, Neranth 1988). This hypothesis was
confirmed when the injection of CRF into the brain ventricles

of rodents immediately inhibited GnRH secretion. Additionally,
they received further confirmation when they injected a CRF
antagonist into the ventricle of the rat brain and it reversed the
inhibitory action of stress on LH secretion (Rivier, Rivest 1991).

The Effects of Stress on GnRH
The primary mechanism in which CRF inhibits GnRH is yet to
be discovered, however; there was another mechanism found
where CRF inhibits GnRH. It was found that when CRF was
infused into both sides of the medial pre-optic area of the hypothalamus, it significantly decreased the GnRH release and plasma LH levels in female rats. Although there seems to consistently be negative effects of stress on the reproductive functions,
the mechanisms will depend on the duration and frequency of
the stimulus. For example, prolonged stress will initially have
the responses mentioned above, but it will consistently inhibit
LH release and then eventually block ovulation all together by
peripheral mechanisms like altering the responsiveness of the
pituitary and gonadal systems.
Most studies that were done agree that a very common cause
of stress induced anovulation is by the mechanism of reduced
hypothalamic GnRH input, which is caused by stress. If there
is a decline in the GnRH secretion, it will directly reduce the
secretion of LH and FSH and could wholly or partially disrupt
folliculogenesis (Bourga, Loucks 2001). Bourga and loucks discovered that amenorrheic athletes had less luteal progesterone
secretion, fewer LH pulses per day, and higher cortisol levels.
Furthermore, they also found that amenorrheic athletes that
were anovulatory had the fewest LH pulses in a day and the
highest cortisol levels. However, most of the studies done focused on specific stressors and how they affected a women’s
cycle or ovulation. Not many studies were done on how real
life, daily stress has on reproduction.

Daily Stress and its Effects on Reproductive
Hormones
A mechanism on how daily stress affects women was provided
to us by a study done by Nepomensachy Et Al. 2004. In contrast
to our prior evidence, Nepomensachy and his fellow researchers found an alternative mechanism by which stress affects the
reproductive hormones. As we have seen in previous research
articles, stress is believed to affect reproductive function through
a reduction in gonadotropins, which leads to a reduction in gonadal steroids.This also involved the stress activation of the HPA
axis triggering the release of corticotropin-releasing hormone.
The increase in CRH negatively affects the GnRH pulsatility and
the cortisol surge causes a reduction of sensitivity to GnRH,
leading to a reduction in the release of Gonadotropins (River,
Vale, 1990). Because of the reduction in gonadotropin levels,
it altered the maturation of the follicle, which delayed or prevented ovulation, with many other effects on the reproductive
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hormones. However, in another study by Xiao et al 2000, they
showed a different mechanism. They showed that while many
other studies showed that intense levels of inflammatory stress
inhibited the secretion of LH in female monkeys, in their studies
they found that inflammatory stress can actually promote LH
secretion. This was an interesting phenomenon as the monkeys
also showed a rise in progesterone, and a rise in LH. Usually,
when there is a rise in progesterone, it usually inhibits the secretion of LH (Xiao et al 2000).
In the study done by nepomnaschy, a new mechanism was
discovered. They did not discover that the inhibition of progesterone during the luteal phase was triggered by a reduction
in the levels of follicular gonadotropins. Rather, their results
showed that during the mid-luteal phase, elevated cortisol levels
predicted low progestin levels, however; during the follicular
phase, higher cortisol levels were associated with higher, not
lower, gonadotropin levels. However, whether the mechanism
that stress effects by lowering the gonadotropin levels, or increasing the gonadotropin levels, still has detrimental effects on
the ovulation and implantation process. Low progesterone levels may cause a degenerative endometrium, and even if normal
ovulation does occur, there may be a problem with implantation
(Nepomnaschy, et. al.,2004). In order for a normal, healthy pregnancy to occur, there needs to be a normal implantation, and it
is critical for the progesterone levels to be balanced.
Although it may seem that different types of stress may have
different effects, it has also been shown that people that are
more sensitive to stress, will have different responses. In contrast to studies that were done on humans, there was a study
done by Herod, Dettmar et al. on monkeys in order to see
which specific type of stress produced the most effects on the
reproductive dysfunction. In their experiment, they found that
the Monkeys with high cortisol levels varied according to the
specific physical locations the monkeys were in, and which type
of stress they were exposed to. It was found with their monkeys
that they did show elevated cortisol in response to mild psychosocial plus metabolic stress. Also, the stress sensitive monkeys
showed much higher cortisol levels than non-stressed monkeys.
This finding would support the hypothesis that individuals with
stress-induced amenorrhea do not have elevated baseline cortisol levels, but they are rather more likely to experience stress
and thus have a higher probability of having elevated stress-induced cortisol when studies are performed.
Additionally, we know and have proven that elevated CRH
suppresses the hypothalamic-pituitary-gonadal axis. However,
the findings in Herod’s studies with monkeys do not rule out
a role for CRH acting as a neurotransmitter rather than a neuroendocrine hormone in causing sensitivity of the reproductive
axis to stress. Increased CRH gene expression may be acting in
a non-neuroendocrine manner to regulate other neurotransmitter systems that mediate functions of the reproductive axis,
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including norepinephrine, dopamine, serotonin, γ-aminobutyric
acid, and glutamate. Stress Sensitive monkeys have suppressed
physiological release of serotonin, fewer serotonergic cells, and
low expression of a number of genes in the serotonin pathway.
However, when they were treated with a selective serotonin
reuptake inhibitor, it increased the ovarian steroid hormone
secretion. Thus, it caused the other functions to start working properly. This study may have given us a new mechanism
by which the ovulatory system can be disrupted, by inhibiting
neurotransmitter secretion (Herod, et al 2011).

Conclusion
The mechanisms by which stress negatively affects ovulation is
an amazing phenomenon with many mechanisms still yet to be
discovered. Whether it is because of a physiological stress or
physical stress, there have been a various amount of mechanisms that have been discovered, with many of them mentioned
in this paper. While many of the mechanisms involved a premature LH surge, an increase in LH, inhibition of GnRH, Inhibition
of FSH or excessive FSH, there were a variety of mechanisms
that led to each outcome. Of all the mechanisms, there was
not one specific one that dominated the others. Different stress
caused different biological responses to occur, yet they all led
to menstrual or ovulatory dysfunction. This data is extremely
important as knowing exactly which mechanism is responsible
for the menstrual or ovulatory dysfunction is imperative for
assessing proper treatment. A suggestion for future research
would be to see if stress affects ovulation subtly without causing
amenorrhea.
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Abstract
The United States has been noted as the country with the greatest caffeine consumption in the world. More than half of all
Americans are said to consume caffeine on a daily basis. Caffeine is easily available in a variety of dietary products including coffee, tea, soft drinks, and chocolate. Many pregnant women are unaware of the potential risk that excessive caffeine consumption
can have on their unborn child.The purpose of this paper is to explore the ramifications of caffeine intake on a fetus.The studies
reviewed propose that heavy maternal caffeine consumption, that of more than 300 mg daily, is associated with increased risk
of spontaneous abortion or delivery of an infant of low birth weight. Most researchers agreed that caffeine does cause preterm
labor and delivery, nor does it act as a human teratogen.
Acronyms

Distribution

LBW- Low Birth Weight
SGA- Small for Gestational Age
IUGR-Intrauterine Growth Retardation

The distribution volume of caffeine within the body is 0.7 L/
kg, demonstrating caffeine’s hydrophilic quality and ability to
distribute freely into intracellular tissue water (Arnaud, 1993).
Caffeine can also pass through all biological membranes and
freely crosses the blood-brain barrier, demonstrating its lipophilic quality (Institute of Medicine, 2001). In pregnant women,
the caffeine can cross the placenta to the fetus, and as early as
7-8 weeks gestation, maternal and fetal plasma can achieve an
equilibrium (Goldstein,Warren, 1962). A fetus swallows approximately 500 mL of amniotic fluid daily, and studies suggest that
several milligrams of caffeine can be ingested along with the
fluids. Additionally, by week 12 of gestation the fetal liver is able
to methylate theophylline to caffeine (Brazier, 1981). Both caffeine and theophylline are eliminated in the amniotic fluid, with
caffeine’s fetal elimination half-life at approximately 150 hours,
while theophylline’s is 30 hours.

Introduction
Caffeine (1,3,7-trimethylxanthine) is a naturally occurring compound. Its pharmacological and physiological effects include
stimulation of the central nervous system and cardiac muscle,
and relaxation of smooth muscle. Caffeine has been shown to
have effects on physical and cognitive performance, as well as
mood, memory, and alertness. Caffeine is the most widely used
stimulant for the central nervous system. Clinically, caffeine is
useful for relaxing the bronchial muscle in asthmatic patients,
increasing secretion of gastric acid, and the concentrations of
plasma free fatty acids, and glucose (Institute of Medicine, 2001).

Sources of Caffeine
Coffee, tea, and soft drinks are the main sources of caffeine in
the diet of the average American adult. Other dietary sources
include chocolate and cocoa, sugars and sweets, and flavored
dairy products.Tea also contains a significant amount of theophylline (1,3-dimethylxanthine), as cocoa also contains theobromine (3,7-dimethylxanthine), both being derivatives of caffeine
that have not been as widely researched (Frary, 2005). Many
classes of nonprescription medications including analgesics,
cold/allergy products, diuretic products, stimulants, and weight
control agents have some caffeine content. All medications have
a suggested dose, but consistent usage may lead to the medication becoming a significant source of caffeine consumption.

Absorption, Distribution, and Elimination of Caffeine
Absorption
Caffeine and the other methylxanthines are quickly absorbed in
humans.As much as 99 percent is absorbed within the 45 minutes
after ingestion. Oral, rectal, and parenteral administration is possible, with the oral route being most common.When consumed in a
beverage, the caffeine is quickly absorbed from the gastrointestinal
tract and distributed throughout body water. Caffeine in preparations that allow absorption through oral mucosa, such as caffeinated chewing gum, are absorbed even more rapidly. Depending
on the source of the caffeine and the individual’s metabolism,
caffeine’s peak plasma levels appear between 15 and 120 minutes
after ingestion or administration (Institute of Medicine, 2001).
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Elimination
The small fraction of caffeine that is excreted unchanged in
urine indicates that caffeine metabolism is the rate-limiting factor in its plasma clearance. Its limited appearance in urine is due
to caffeine being readily reabsorbed by the renal tubules and filtered by the glomeruli (Arnaud, 1993). Frequent caffeine ingestion has not been shown to affect its absorption or metabolism
in healthy humans. The bulk of caffeine metabolism takes place
in the liver, catalyzed by hepatic microsomal enzyme systems
(Grant et. al., 1987). In the liver, caffeine is metabolized to dimethylxanthines, uric acids, di- and trimethylallantoin, and uracil
derivatives. 3-ethyl demethylation to paraxanthine is shown to
be the most frequent route for caffeine metabolism in humans
(Arnaud, 1987). This is the first step in caffeine metabolism and
accounts for approximately 75–80 percent of the process. Being
the chief metabolite in humans, paraxanthine is found to have a
plasma concentration ten times higher than those of theophylline and theobromine. Eight to ten hours after ingestion, plasma
levels of paraxanthine surpass those of caffeine, as caffeine is
cleared more rapidly than paraxanthine (Arnaud, 1993). During
the second and third trimesters of pregnancy, maternal caffeine elimination rates drop due to changes in progesterone
and estrogen levels, with the half-life of caffeine changing from
5.3 hours to 18.1 hours. Maternal clearance of caffeine during
pregnancy can be decreased further by other factors, including
smoking and long-term use of oral contraceptives, as well as age
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and disease. Within a couple of weeks of giving birth, a women’s
caffeine metabolism rate returns to the same rate as prior to
pregnancy (Aldridge et. al., 1981).

Methods
Critical analysis of peer reviewed journal articles and original
clinical research papers was used to write this review. The articles and papers were obtained with access to online publications through the Touro College library. Additional references
were obtained through Pubmed and Google Scholar.

Effects of Caffeine Consumption on Birth Weight
A low birth weight (LBW) infant is one who weighs less than
2,500 g (5 lbs, 8 oz) at birth. Prematurity due to a shortened
gestational period can cause low birth weight, but LBW can
also be the consequence of intrauterine growth retardation
(IUGR), which results in a small for gestational age (SGA) infant. Intrauterine growth retardation is classified as less than
the 10th percentile of birth weight for gestational age in comparison to an external standard of birth weight for gestational
age, adjusted for gender and ethnicity, that was developed from
all 1999 singleton births in the United States, and updated in
2014 (Talge et. al., 2014). Many studies have shown a strong correlation between caffeine intake during pregnancy and reduced
birth weights. For pregnant women who consume more than
300 mg of caffeine daily, a high risk of SGA and IUGR has been
found. Intake between 150 mg and 300 mg daily has also been
linked to such risks; however, the data is not as consistent.
From 2003-2006, a perspective cohort study following pregnant women between the ages of 18 and 45 with singleton pregnancies was implemented. The caffeine intake of these women
was monitored, and the relationship between caffeine and fetal
growth was evaluated. At any level of caffeine intake there was
an associated risk of fetal growth retardation found, and this risk
was maintained throughout pregnancy. They found that after
adjustment for smoking and alcohol intake, an average caffeine
consumption of more than 100 mg per day was correlated with
a reduction in birth weight of 34-59 g in the first trimester,
24-74 g in the second, and 66-89 g in the third. An extra 60-70 g
may seem insignificant, but it can make all the difference for an
already compromised fetus, and can help avoid perinatal morbidity and mortality. The study did observe a large decline in
risk for a daily caffeine intake of less than 30 mg, but this may be
due to unmeasured confounding, or simply because lower caffeine intake is probably more common among women who have
healthier diets and habits in general (CARE Study Group, 2008).
A second prospective study observed the caffeine intake of
9,921 healthy pregnant women throughout their third trimester.
Fifty-three of the women reportedly consumed more than five
cups of coffee daily, and they were found to have a 13.2% higher
prevalence of fetuses who were SGA (Fuhurhashi et. al., 1985).

The Norwegian Mother and Child Cohort Study conducted
by the Norwegian Institute of Public Health followed 59,123
women with uncomplicated singleton pregnancies. At weeks 17,
22, and 30, the women reported their caffeine intakes from different sources. SGA was defined according to ultrasound-based,
population-based, and customized growth curves. Based on the
three scales, an average of 25 g weight reduction was associated
with every additional 100 mg of maternal caffeine intake per day
for a baby with an expected birth weight of 3,600 g. Coinciding
results for caffeine sources, time of survey, and different definitions of SGA were found for this, substantiating its results.
Even caffeine consumption below the recommended maximum
such as 200 mg per day, compared to the recommended 300 mg
per day, was consistently associated with increased risk for SGA
(Sengpiel, 2013).
Gestational age was not linked to caffeine intake in these
studies, suggesting that the effect maternal caffeine consumption has on fetal birth weight occurs through IUGR. Possible
mechanisms responsible for this effect include caffeine’s similar
structure to adenine and guanine which may allow it to interfere
with cell division and metabolism. Additionally, caffeine has a vasoconstrictive effect on placental intervillous blood flow, which
may be a factor to increase the risk of IUGR (Kirkinen, 1983).
During the first trimester of pregnancy, the embryo first
starts developing its organs, heartbeat, brain waves, and the
rest of its body parts. As this is such a crucial time of development, caffeine intake should be limited especially then. In fact, a
greater reduction in risk for IUGR and delivering LBW infants
was found among women who reduced their caffeine intake to
less than 300 mg within 6 days of their last menstrual period,
compared to those who reduced their intake later in pregnancy
(Fenster et. al., 1991).
There is a steady negative correlation between LBW infants
and daily maternal caffeine intake above 300 mg. In many studies,
a daily caffeine consumption between 151 and 300 mg, and occasionally even 150 mg or lower has been associated with risks
of low birth weight. Pregnant women should be sure to limit
their caffeine intake as much as possible to lessen the probability of reductions in infant birth weight. The seemingly slight
decrease in weight can be very harmful for premature infants
or infants who are otherwise compromised. Further research
is needed to clarify the mechanisms by which caffeine exercises
an effect on fetal growth.

Effects of Caffeine Consumption on Preterm
Labor and Delivery
Caffeine has not been found to be a strong factor in increasing the risks of preterm labor and delivery. In 1996–2000,
2,291 mothers with singleton pregnancies in Connecticut
and Massachusetts were questioned about caffeine consumption and other important confounding factors after their first
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prenatal visit. Urine samples were taken to analyze urinary caffeine, cotinine, and creatinine levels.The mothers were followed
throughout pregnancy to monitor changes in consumption,
and medical records were obtained to confirm pregnancy outcomes.While mean birth weight was found to be reduced by 28
g per 100 mg of daily caffeine intake, mean gestational age was
not found to be affected at all (CARE Study Group, 2008).
In the Norwegian Mother and Child Cohort Study, spontaneous preterm delivery was defined as “spontaneous onset of
delivery between 22+0 and 36+6 weeks (n = 1,451)”. Caffeine
from coffee, but not from other sources, was actually associated
with prolonged gestation, but no association of increased risk
of spontaneous preterm delivery was found with caffeine consumption (Sengpeil et. al., 2013).
Other studies as well found no effect on gestational age, indicating that caffeine influences fetal growth, not gestational age
at delivery. Pastor et. al performed a case control study of 408
preterm (less than 37 weeks gestation) infants, and analysis of
caffeine intake in the third trimester showed a nonsignificant
relationship with preterm delivery (Pastore, Savotz, 1995).
Alternatively, in a population-based study of 7,855 livebirths,
increased preterm birth among women who drank caffeinated
coffee was found compared with women who drank neither
decaffeinated nor caffeinated coffee. Those who consumed only
decaffeinated coffee showed no increased odds of SGA birth,
LBW, or preterm delivery, while women who consumed caffeinated coffee alone had a higher association with preterm delivery (Eskenzai et. al., 1999). This study has not been replicated,
and other analyses did not support it.
Gestational age is difficult to calculate and assess, making
this topic more difficult to analyze accurately. Generally, there
appears to be no relationship between caffeine consumption
during pregnancy and premature labor and delivery in humans.

Effects of Caffeine Consumption on Spontaneous
Abortion
Most studies report effects of caffeine on spontaneous abortion,
however, there are some who suggest otherwise. In one study,
2,967 pregnant women who delivered at Yale-New Haven hospital between 1988 and 1992 were evaluated for caffeine intake
during the first month of pregnancy. After studying the effect
of the caffeine on pregnancy outcomes, it was concluded that
increased risk of spontaneous abortions was linked to drinking
more than 3 cups of tea or coffee daily. The association of risk
with tea and coffee intake was shown to be stronger than with
caffeine in general, and was primarily correlated with abortions
which took place in later trimesters (Dlugosz et. al.,1996).
A prospective cohort study of 3,135 pregnant women found
that those who consumed more than 151 mg of caffeine daily
were more likely to spontaneously abort in the second or third
trimester, in comparison to those who had a daily intake of less
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than 150 mg of caffeine (Srisuphan, Bracken, 1986).
A study of healthy, pregnant women, all of whom were beyond 24 weeks of gestation revealed that caffeine consumption
of more than 600 mg daily was significantly associated with
impending abortion, with a higher prevalence of 17% found
(Fuhurhashi et. al.,1985).
Another study of 1,324 women demonstrated associations
between caffeine intake prior to and during pregnancy with
spontaneous abortions in 331 of the 1,324 women. The risk of
fetal loss increased for each 100 mg of caffeine ingested daily
during pregnancy, as well as smaller increases in risk for each
100 mg of caffeine ingested daily prior to becoming pregnant
(Infante-Rivard, 1993).
Dominguez-Rojas et. al conducted a retrospective cohort
study of 711 pregnant women, monitoring their caffeine intake,
and found caffeine to be a clear risk factor for spontaneous
abortion. They determined that the adjusted odds ratio (a measure of association between exposure and outcome) of spontaneous abortion by caffeine consumption was significant for
141-280 mg daily, doubled for 281-420 mg daily, and then almost
tripled for intake of greater than 421 mg daily (DominguezRojas et. al., 1994).
Alternatively, different studies found no association between
maternal caffeine intake and spontaneous abortions. Four hundred and thirty-one women were enrolled in a multicenter study
within 21 days of conception. Throughout pregnancy, they were
monitored for caffeine intake, and exposure to other risk factors,
and the effects on pregnancy outcome.The investigators found no
connection between caffeine intake, neither above or below 30
mg daily, and increased risk of spontaneous abortions (Mills, 1993).
Determining a definite causal connection between caffeine
intake and occurrence of spontaneous abortions is difficult,
as many of the studies that have been done did not control
properly for other factors such as smoking, parity, or alcohol
intake. There seems to be a strong association between caffeine
consumption and fetal loss, but more research must be done
before unambiguous statements can be made.

Effects of Caffeine Consumption on Congenital
Malformations
Caffeine can perhaps act as a teratogen due to its chemical
structure as a purine, one of the components of DNA. After
maternal consumption, caffeine can cross the placenta to the
developing embryo. If the molecule were to become incorporated into DNA, there is a possibility that it could induce the
production of abnormal proteins (Goldstein, 1962). The literature reviewed showed no significant evidence linking human
maternal caffeine intake during pregnancy to major congenital
malformations.
In a study performed to analyze information from the Finnish
Registry of Congenital Malformation, mothers who had given
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birth to infants with the same defects were matched according
to place and time of birth. One mother in each pair consumed
coffee during pregnancy, while the other did not.To evaluate the
hypothesis that coffee consumption during pregnancy is teratogenic, the 706 pairs of mothers of malformed children and their
controls were interviewed soon after delivery. The subjects of
the study included 112 mothers of children with defects of the
central nervous system, 241 mothers of children with orofacial
clefts, 210 mothers of children with structural defects of the
skeleton, and 143 mothers of children with cardiovascular malformations. The study determined that coffee intake does not
appear to increase risk for any of the defects that were studied.
Even mothers who consumed more than six cups of coffee per
day had no higher risk of giving birth to an infant with congenital malformations. The study also paired these mothers with
women who gave birth to non-defective infants, in the same
time and place, and who consumed an equivalent amount of
caffeine daily during pregnancy. The amount of coffee consumed
during pregnancy was similar for the mothers of malformed
and non-malformed children, with the broad range of maternal
intake being 0-10 cups daily, demonstrating that excessive coffee intake does not increase risk of congenital malformations
(Kurppa et. al., 1983).
Mcdonald et al. investigated the relationships between smoking, alcohol intake, and caffeine consumption, and congenital
malformations using data from a survey conducted in Montreal
from 1982-1984. A weak association between caffeine consumption and heart defects was found, but the evidence was
not strong. There was no connection found between caffeine
intake and club foot, clefts, neural tube defects, or musculoskeletal renal/urinary, gastrointestinal, or respiratory abnormalities
(Mcdonald et al., 1992).
Similarly, a study was performed to determine the possible effects of different chemical and physical factors during pregnancy
on the occurrence of cardiovascular malformations, specifically
hypoplastic left heart syndrome. Using a standard questionnaire,
573 cases and 1,055 controls were interviewed approximately 3
months after delivery. An increased risk of cardiovascular malformations was not found to be associated with coffee, tea, or
cola consumption (Tikkanen, Heinonen, 1994)
One study did show an increased risk for malformations due
to caffeine. A retrospective case-control study was executed in
which 558 women in England who had delivered an anencephalic stillbirth were matched with 2,232 control women based
on maternal age, parity, and date of delivery. Based on a structured questionnaire completed by the cases and controls, it was
shown that the women who drank 3 or more cups of tea daily
were more likely to give birth an anencephalic stillborn (Fedrick,
1974). However, the results of this study may not be completely
accurate, and the authors themselves wrote that caution should
be taken when interpreting their results.

Most studies agree that there is no connection between caffeine intake during pregnancy and congenital abnormalities. Any
connections that were found have been deemed weak at best.

Conclusion
Maternal caffeine intake during pregnancy should be limited to
between 150 mg and 300 mg per day, to mitigate negative effect
caffeine has been shown to have on birth weight, risk of IUGR,
and risk of spontaneous abortion. More studies must be done
to confirm correlation between caffeine and spontaneous abortion, and based on current data, there does not seem to be a
significant risk of preterm labor or congenital malformations
related to caffeine intake.
Pregnancy is a time when motherly instincts begin to kick
in, and women are likely to be receptive to counseling about
lifestyle changes. Many women are unaware of the real risk that
their caffeine intake can create for their unborn child. Doctors
and prenatal counselors should be sure to discuss the matter
with soon-to-be mothers so they can make informed decisions
when consuming caffeine during pregnancy. In addition, having a
health care provider monitor caffeine intake may help establish
the degree of risk for use of other drugs or high-risk behaviors
during pregnancy.
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Abstract
Incidence of dementia has been on the rise over the last few decades and it is projected that more than 130 million people will be
affected by dementia worldwide by 2050. The underlying cause remains incompletely determined, and despite numerous clinical
trials, no drug to date has proven effective in preventing or reversing symptoms of cognitive decline due to Alzheimer’s disease.
The amyloid hypothesis as a basis for drug development of Alzheimer’s disease has thus far proven to be ineffective, suggesting
that perhaps a new approach is required. New studies have shown the efficacy of a multi-domain approach which targets several
disease risk factors simultaneously, to achieve a synergistic effect on cognitive impairment. This paper analyzes a multi domain
protocol, known as ReCODE protocol, developed to treat and prevent Alzheimer’s disease, and provides clinical and experimental
research as well as potential mechanisms to support the key elements upon which this protocol is based. Although the results
seem promising, more rigorous clinical testing is required to link this approach with prevention and reversal of cognitive decline
more definitively.
Acronyms

Alzheimer’s disease (AD), amyloid beta (Aβ), β-Amyloid Precursor
Protein (APP), Reversal of Cognitive Decline (ReCODE),
tumor necrosis factor (TNFα), interleukin-6 (IL-6), interleukin-1β (IL-1β), Apolipoprotein E4 (ApoE4), Positron Emission
Tomography (PET), Presenilin 1 (PS1), homocysteine (HC), Beta
Hydroxybutyrate (β-HB), ketone bodies (KB), acetoacetate (Ac)

Introduction
Today, nearly 50 million people worldwide are living with dementia (Prince et al., 2016). As one of the leading causes of
age-related cognitive decline, Alzheimer’s disease (AD) represents a significant health concern for the aging population.The
underlying cause remains incompletely determined, and to date
no effective treatment has been discovered. Although remarkable progress and scientific breakthroughs in recent decades
have led to the development of effective protocols for diseases
such as HIV and cancer, treatment therapies for neurodegenerative diseases such as Lewy body dementia and Alzheimer’s
disease continue to lag significantly behind. Despite billions of
dollars funneled into hundreds of clinical trials on various drug
modalities, no truly effective etiological treatment or prophylactic medication has been approved by the FDA to date. Of
the five drugs that have been approved to treat the cognitive
symptoms of Alzheimer’s disease, none have been shown to
have more than a marginal or sustained effect on symptomatic
patients with AD.

The Amyloid Hypothesis
AD onset is associated with a complex neurodegenerative cascade mechanism histologically characterized by parenchymal
deposition of amyloid-β (Aβ) and intracellular neurofibrillary
tangle formation due to hyperphosphorylation of tau protein
(Cunnane et al., 2011). Since the discovery of the Aβ peptide
in 1984, the amyloid hypothesis has largely been the paradigm
in understanding AD and the basis for researching potential
therapeutic treatments. The amyloid hypothesis posits that
the formation of senile plaques, composed predominantly of

the proteinaceous Aβ peptide, leads to synaptic toxicity and
cognitive deficits in AD (Banwait et al., 2008). In recent years,
however, the validity of this theory has come into question;
for although the neurotoxicity of Aβ is supported by substantial
genetic and biochemical data, Aβ-centered therapeutic trials
aimed at limiting the production of amyloid or facilitating its
removal have failed to prove clinically effective in slowing cognitive decline in AD patients (Pimplikar, 2009). These results
suggest that perhaps, rather than being the primary cause of
the disease, Aβ is a “downstream response to injury, with both
beneficial and injurious properties” (McCaully & Grush 2017).
With the entire premise of the current Alzheimer’s paradigm
under question, it seems that perhaps a new understanding of
the role of Aβ is necessary.

Paradigm Shift
Dr. Bredesen and associates address the inconsistencies of the
prevalent amyloid cascade theory and clinical outcomes with
a new approach, radically different than its monotherapeutic
precedents. They have advanced a model in which, “AD results
from an imbalance in endogenous plasticity signaling, and in
which the β-amyloid precursor protein (APP) is a mediator of
such plasticity-related signaling,” suggesting an etiology analogous to chronic illness such as osteoporosis and arthrosclerosis. Osteoporosis occurs when there is a chronic imbalance
between osteoblastic and osteoclastic signaling and new bone
formation is exceeded by old bone resorption. “By analogy, in
Alzheimer’s disease, there is a fundamental age-associated imbalance between the dynamically opposed physiological processes that mediate plasticity, i.e. between synaptoblastic and
synaptoclastic activity” (Bredesen, 2014).
Aβ is a peptide produced by the proteolytic cleavage of its precursor protein, APP, mediated by γ-secretase and β-secretase
1 (Heneka et al., 2014). This integral membrane protein can
be cleaved via two alternative pathways and in this way act as
a molecular switch to mediate neuroplasticity. Amyloidogenic
processing of APP leads to cleavage at the beta, gamma, and
caspase sites to produce pro-AD peptides sAPPβ, Aβ, Jcasp, and
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C31 - all of which have been shown to mediate neurite retraction and caspase activation. In contrast, the non-amyloidogenic
processing of APP through cleavage at the alpha site results in
the formation of sAPPα and αCTF, peptides which mediate neurite extension and inhibit Aβ production and caspase activation
(Bredesen, 2014; Chen, 2017).
In studies using regular and transgenic mice, both genetic
and pharmacologic methods were used to manipulate the APP
derivative peptide balance and were found to cause predictable effects on learning and memory. This suggests that the APP
cleavage pathway may be a potential target to inhibit AD pathophysiology. A number of agents that affect this pathway, including
nitrin-1 and Aβ, have been identified, however, targeting any of
these agents individually has had limited success. Additionally,
other potential intervention targets, aside from Aβ oligomers,
including inflammatory mediators, apolipoproteins, trophic factors and their receptors, and axoplasmic machinery have been
identified. Although targeting any one of these pathways shows
great promise in preclinical studies, it has not proven effective
in human studies. This inconsistency seems to suggest that a
“network-based therapeutics approach, rather than a single target-based approach, may be more effective for the treatment
of cognitive decline due to Alzheimer’s disease” (Bredesen,
2014). The complex, multifactorial nature of the disease may
require interventions that target several risk factors and disease
mechanisms simultaneously for optimum effect. Comprehensive
combination therapies have been shown to greatly improve
treatment of other chronic illnesses, such as HIV and cancer.
In the case of HIV, the development of highly active antiretroviral therapy, a form of combination therapy, caused a significant
decline in death rates for a disease that had been minimally
treatable for decades (Brady et al., 2010).

The Finger Study
The Finnish Geriatric Intervention Study to Prevent Cognitive
Impairment and Disability (FINGER) assessed a multi-domain
approach towards improvement of cognitive functioning and
prevention of cognitive decline in the first extensive, long-term,
methodologically rigorous trial to date. They conducted a twoyear trial to confirm the associations of several modifiable factors, such as diet and physical inactivity, with Alzheimer’s disease.
Participants were required to be between 60-77 years of age
and have a minimum CAIDE (Cardiovascular Risk Factors,Aging,
and Dementia) Score of 6 points. The Consortium to Establish
a Registry for Alzheimer’s disease Neuropsychological Battery
Test was used for cognitive screening. Only participants who
tested at or slightly lower than the mean level of cognitive performance, as compared to the normal population, were included
in the study. Individuals with diagnosed or suspected dementia,
and several other disorders or impairments were excluded.
Participants were randomly assigned to the intensive
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multi-domain intervention or regular health advice group (control
group) using computer-generated allocation at each of six testing
centers.The trial was double-blinded to the maximum possible extent, wherein allocation was not disclosed to either participants or
outcome assessors. Participants were restricted from interacting
with each other and advised not to discuss their experiences.

Procedures
All participants met the study nurse five times during the two
year trial where they received advice on a healthy diet, and physical, cognitive, and social activities to manage risk factors and
prevent cognitive impairment. The intervention group received
four additional components, including a nutritional intervention,
a physical exercise training program, cognitive training, and social activities.

Results
There was significant improvement for the primary outcome
in the intervention group, which showed 25% greater improvement in the neuropsychological test battery (NTB) total score
than the control group. The intervention group also showed
higher improvements in executive function and processing
speed than the control group, 83% and 150% respectively. There
was no evidence, however, of significant change in memory for
the intervention group (Ngandu et al., 2015).

A More Comprehensive Multi-Domain Approach
to Treatment of Alzheimer’s Disease
The ReCODE Protocol
The ReCODE Protocol outlines a more comprehensive therapeutic system that targets as many as 36 risk factors or disease
mechanisms to prevent and reverse cognitive decline. While
the individual effects of any one of these factors may not be
significant, the protocol targets many factors simultaneously to
create a synergistic effect capable of reversing the imbalance
of synoblastic/synoclastic activity mediated by APP. Typically, the
evaluation of patients with cognitive decline does not include
testing for genetics, inflammation, infection, homocysteine, fasting insulin level, toxic exposure, blood brain barrier or body
mass index, all of which are known risk factors for AD. Patients
following the ReCODE Protocol undergo extensive lab and genome testing, referred to as a “cognoscopy,” to identify genetic
risk factors and suboptimal physiological, metabolic, and cognitive parameters.The results are used to generate a personalized
ReCODE Report™ which designs an individualized protocol
targeting the identified risk factors in order to synergistically
achieve an optimum outcome (Bredesen, 2017).

Three Subtypes of Alzheimer’s
To optimize treatment development, Bredesen et al. uses
metabolic profiling to distinguish between three subtypes of
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Alzheimer’s disease, each with its own characteristic biomarkers. Although there may be overlap, each subtype requires remediation of specific suboptimal indicators.

Subtype 1: Inflammatory
Carriers of the apolipoprotein E4 (ApoE4) gene are at increased risk for developing AD, particularly the inflammatory
subtype. Carriers homozygous for the ApoE4 allele often become symptomatic as early as late forties or fifties, single ApoE4
allele carriers in late fifties or sixties, while symptom onset for
those without the gene is typically in the sixties to seventies.
This subtype is associated with biomarkers of systemic inflammation such as increased hs-CRP, IL-6 and TNFα as well as a
decreased albumin:globulin ratio. Symptomatically, this subtype
is characterized by the loss of the ability to form new memories
while retaining long-term memories and the ability to calculate,
spell, and write. Brain atrophy of the hippocampus is evident
early in the disease progression (Bredesen, 2017).

The Inflammation Hypothesis
Inflammation has been implicated in AD mechanisms and is
believed to play a critical role in the pathogenesis of the disease. When Aloysius Alzheimer studied the post-mortem brain
of Aguste Deter in 1907, he found microglia, the primary cells
of the innate immune system involved in the brain inflammation response, clustered around the amyloid plaques. Initially,
the inflammation hypothesis was regarded as unlikely or even
impossible due to the view of the brain as an “immune-privileged organ,” allowing for inflammation only “through direct
infection or after the breakdown of the blood brain barrier and
subsequent infiltration of peripheral immune cells” (Heneka et
al., 2014). However, extensive research over the last decade has
confirmed the presence of neuroinflammation in AD and suggests that its presence may even begin in preclinical stages of
the disease (McCaully & Grush 2017). PET imaging has shown
evidence of significantly increased levels of neuroinflammation
markers in brain areas affected by AD neuropathology while
almost no neuroinflammation was found in individuals without dementia, despite high plaque burden (Krstic et al., 2012).
Furthermore, several known risk factors for AD, such as a history of systemic infection, obesity, and reduced physical activity,
are associated with some component of inflammation (Heneka
et al., 2014). Increasing evidence suggests that neuroinflammation seems to correlate more directly with cognitive decline
than plaque deposition alone.

Innate Immunity: Microglial Contribution to
AD Pathogenesis
Innate immune cells, particularly microglia, have been implicated as mediators of neuroinflammation in AD and as contributors to its pathogenesis. Microglial cells are an essential part

of the central nervous system and serve to protect the brain
from injury and pathogenic invasion. In brain development, microglia assist in synapse formation and eliminate dysfunctional
synaptic connections (Van Eldik et al., 2016). Rice, et. al. (cited
in Spangenberg & Green, 2017) found that healthy adult mice,
without a proliferation of microglia, showed 35% more synapse-bearing dendritic spines than mice with significant microglial proliferation, indicating that microglial participation in synaptic maintenance may continue even into adulthood through the
dismantling of dendritic spines in the AD brain.
In the homeostatic adult brain microglia are in a “surveillance
state,” constantly surveying the brain parenchyma to detect
abnormalities and supporting neuronal health and function by
regulating synaptic plasticity and pruning unnecessary synapses.
Upon detection of an insult, such as Aβ plaques, these immune
cells are activated and assume an entirely different phenotype
with both chemical and morphological changes, including the
retraction of their processes.This phenotypic change may inhibit the ability of microglia to alter and adapt synapses and contribute to the impaired synaptic plasticity characterized by AD
(Van Eldik et al., 2016). Once activated, microglia secrete pro-inflammatory cytokines, including TNFα, IL-6, and IL-1β to induce
other cells to migrate to the injury site and mediate clearance
of the invasive material through phagocytosis. In acute inflammatory events, the inflammatory response is resolved through
regulatory proteins which induce microglia to secrete anti-inflammatory factors to promote tissue repair.The microglia then
revert to their “surveillance state”. However, in AD, microglia
are unable to phagocytose Aβ, as evidenced by the presence
of plaques surrounded by microglial cells in post-mortem AD
brains (Spangenberg & Green, 2017). This leads to the sustained
release of pro-inflammatory mediators which “has been shown
to be involved in the suppression of axonal transport and adult
neurogenesis” (Heneka et al., 2014).
Inflammatory dyshomeostasis drives microglia into a state
of chronic activation in which they no longer function properly, resulting in aberrant synaptic pruning, neuronal loss, and
accumulation of Aβ, eventually leading to cognitive dysfunction
(Spangenberg & Green, 2017). Cytokines, for instance, have been
linked to cytoskeletal and synaptic alteration through increased
tau phosphorylation and decreased synaptophysin levels.

Experimental Correlation Between Innate Immune
Activation and Neurodegenerative Disease
Numerous animal studies have linked immune responses to
neurodegeneration. In one study, the NLRP3 gene, an important
component of the neuroinflammatory pathway, was removed
from APP/PS1 mice. This gene knockout resulted in reduced
inflammation, enhanced Aβ clearance, as well as improved synaptic plasticity and cognitive function (Heneka et al., 2013). In
another experimental study, inflammation caused by systemic
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immune challenges alone was revealed to trigger Alzheimer-like
neuropathology in mice. Mice exposed to systemic immune
stimulation prenatally and then again later in adulthood were
predisposed to develop sporadic-like AD during aging. They
displayed chronic microglial activation, increased Aβ deposition,
and working memory impairment (Krstic et al., 2012). In another
study, neutralizing increased levels of the inflammatory cytokine,
IL-1β, was found to reduce Aβ and p-tau in triple-transgenic AD
mice (Ferreira et al., 2014).
A recent study found a correlation between increased proliferation of microglial cells in human AD and disease severity. To
establish the influence of inflammation over the onset and progression of AD they targeted the colony-stimulating factor 1 receptor (CSF1R), a receptor protein that regulates the activation
and proliferation of microglial cells. A tyrosine kinase inhibitor
was administered to APP/PS1 to induce prolonged inhibition of
CSF1R.This inhibition resulted in decreased microglial proliferation and improved performance in memory related tasks.These
results support the “link of the inflammatory response generated by microglia...with the observed synaptic and behavioural
deficits” (Olmos-Alonso, et. al. 2016).
In their review of innate immune activation in neurodegenerative disease, Heneka et al. conclude that neuroinflammation
is likely not only a consequence but also an early cause of the
pathology (Heneka et al., 2014).

Key Measures of Inflammation
C-reactive protein (CRP) is produced by the liver in response
to inflammation. ReCODE protocol advises testing for hs-CRP
(high sensitivity) as the standard CRP test cannot always distinguish optimal levels, below 0.9 mg/dl, from mildly abnormal levels. The albumin to globulin ratio is a complementary measure
of inflammation and should be at least 1.8. Fatty acids omega-6
and omega-3 are pro and anti-inflammatory respectively. Their
ratio should be between 0.5 and 2.9. Levels of cytokines such
as IL-6 and TNFα are also important indicators of inflammation.
Concentration of IL-6 should be less than 3.0 pg/ml and that of
TNFα should be less than 6.0 pg/ml. (Bredesen, 2017)

Reducing Inflammation
The ReCODE protocol recommends a three-pronged approach to reducing inflammation. Treating inflammation is of no
use if the trigger is still present, so first, it is critical to remove
the sources of inflammation by preventing exposure to “inflammagens”. There could be several sources, including chronic
infection, viruses, a diet high in simple carbohydrates, leaky gut,
and even poor oral hygiene. The second step is to resolve the
inflammation through specialized pro-resolving mediator (SPM)
supplements. SPMs are small cell signaling molecules such as
resolvins, and maresins that have been identified during active
inflammation resolution in the body and mediate the return
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to tissue homeostasis (Serhan et al., 2011). Chronic inflammation indicates the inability to return to homeostatic condition
and SPM supplements can provide the missing resolution agonists. The third step is to inhibit new inflammation through
ingestion of anti-inflammatories such as omega-3 and curcumin
(Bredesen, 2017).

Subtype 2: Non Inflammatory or Atrophic
Homozygous and heterozygous carriers of the ApoE4 allele are
at increased risk for this subtype as well, though symptoms typically begin about a decade later than the inflammatory subtype.
Symptoms are similar to those in inflammatory Alzheimer’s, with
an impaired ability to form new memories but retained ability
to write and calculate. Inflammation is not present and some of
its biomarkers may actually be suboptimal. Rather, this subtype
is associated with reduced overall support of synaptic plasticity
marked by an atrophic profile, including insulin resistance, hypovitaminosis D, hyperhomocysteinemia, and reductions in hormonal support from molecules such as estradiol, progesterone,
and testosterone (Bredesen, 2017). While the extent to which
each of these risk factors contributes to AD pathology is still
being studied, scientists have proposed theoretical mechanisms
to support the contribution of many of these mediators, including homocysteine and insulin, to its pathogenesis.

Homocysteine
Epidemiological studies have associated increased levels of homocysteine (HC) with Alzheimer’s disease progression (Morris,
2003). According to one study, homocysteine contributes to
AD pathology through an Aβ-fibrinogen interaction. This interaction induces the oligomerization of fibrin and the formation of abnormal fibrin clots which are resistant to fibrinolysis.
Accumulation of fibrin clots leads to inflammation and disruption of the blood brain barrier. In their study, AD patients with
high levels of homocysteine showed increased Aβ plaques and
fibrinogen levels in the brains. Similarly, researchers induced hyperhomocysteinemia in an AD mouse model by administering a
high methionine diet for several months. These mice displayed
severe Aβ plaque deposition along with learning and memory
impairments (Chung et al., 2016). Homocysteine is a marker of
both inflammation and suboptimal nutritional support. Sufficient
amounts of vitamins B6, B12, and B9 (folate) are required to
maintain an optimal level, below 6 mM/L (Bredesen, 2017).

Insulin Resistance
Insulin resistance is another significant risk factor for AD. Insulin
is degraded by a protein known as insulin degrading enzyme.
This enzyme has also been linked to the decomposition of Aβ
plaques. High levels of insulin require insulin degrading enzyme
to be constantly breaking down excess insulin, thus limiting its
opportunity to decompose Aβ plaques. High levels of glucose

A Multi-domain Approach to Prevention and Reversal of Cognitive Decline

also lead to the production of advanced glycation end products. These molecules trigger inflammation when they bind to
their receptors, cause the formation of free radicals, and damage
blood vessels, thus reducing nutritional support to the brain.
Fasting insulin level should be 4.5 mIU/ml or below and fasting
glucose level should be between 70-90 mg/dL (Bredesen, 2017).

Subtype 3: Cortical or Toxic
Subtype 3 is characterized by biomarkers of toxicity and typically occurs in carriers of the ApoE3 rather than the ApoE4 allele.
Symptom onset is often earlier, in the late forties to early sixties,
and following a period of great stress, sleep loss, anesthesia, or
menopause. Cortical Alzheimer’s is completely different than
the other two types; it is not predominantly amnestic in the
early stages and presents itself instead with cortical deficits such
as dyscalculia and aphasia. In addition to short-term memory
loss, long-term memory loss, including procedural memory, is
also affected (Bredesen, 2017). In these cases, PET imaging often
indicates more general cerebral atrophy compared to the more
restricted temporoparietal reduction typically seen in patients
with subtypes 1 and 2 (Bredesen et al., 2016).
Current research seems to suggest a possible link between
mercury toxicity and AD. In vitro studies have found that mercury increases secretion of Aβ, causes structural changes in
mitochondria which induce a response from the innate immune
system. Mercury also interferes with membrane structures leading to the aggregation of neurofibrillary fibers and degeneration
of neuronal axons (Walach et al., 2015).
Exposure to other biotoxins such as arsenic has also been
shown to affect neurological function. Arsenic exposure most
commonly comes from groundwater, a phenomenon particularly prevalent in western United States where certain areas are
estimated to have over 300 times the permitted EPA level of
arsenic in the drinking water. Gong et al. proposed the Arsenic
Exposure Hypothesis for AD based on premises of existing hypotheses for the disease.They find correlations between arsenic
toxicity and several typical pathological markers of the disease.
These include the following: over transcription of APP, brain inflammatory response, and the generation of free radicals which
cause oxidative stress and neuronal death (Gong et al., 2010).
Although much of the literature on arsenic toxicity details
its cognitive effects on children, recent studies have correlated
it with altered adult cognition as well. The FRONTIER Project
is an ongoing study being conducted on residents living in West
Texas, an area that contains significant levels of arsenic in the
groundwater. Participants with long-term chronic exposure to
arsenic scored lower on tests for global cognition, processing
speeds and immediate memory (Tyler & Allan, 2014).
It has been suggested that Toxic Alzheimer’s is a phenotypic manifestation of chronic inflammatory response syndrome
(CIRS), commonly caused by exposure to biotoxins such as

molds or tick-borne pathogens. Cognitive decline in both
patients with CIRS and Type 3 Alzheimer’s is not limited to
amnestic symptoms; it includes executive dysfunction often
concomitant with hypozincemia, dysfunction of the hypothalamic-pituitary-adrenal axis, and psychiatric effects such as depression. In the case studies of patients displaying type 3 symptoms,
all of them had a history of significant toxic exposure (Bredesen,
2016). Patients with the toxic subtype of Alzheimer’s also often
present significantly high levels of copper and low levels of zinc
which can cause increased sensitivity to toxins such as mercury
and mold. A copper:zinc ratio of 1.4 or higher has been associated with dementia.
ReCODE recommends treating metal toxicity in one of several ways including chelation, or a gentler method called Detox
Qube which helps optimize the natural detoxification process
of the body to eliminate potentially toxic metals such as mercury and arsenic. Treatment for toxicity from other toxins such
as mold are more complicated and exposure specific and thus
should be treated by a physician experienced in biotoxin-associated illness (Bredesen, 2017).

Additional Factors Addressed by ReCODE
The primary characteristic of the ReCODE protocol is its
attempt to simultaneously address as many potential disease
mechanisms as possible, including diet, exercise, and cognitive
training, among others.

Ketogenic Diet: A Neuroprotective Mechanism
The protocol recommends that patients adhere to a ketogenic
diet which has been associated with neuroprotective benefits.
Ketogenic diets have been linked to several neuronal and synapse supporting mechanisms. Studies have associated a ketogenic diet with antioxidant effects, increased cerebral ATP indicating
metabolic effects, and decreased expression of pro-apoptotic
factors clusterin and caspase-3, implicating anti-apoptotic mechanisms as well. Additionally, it has been found that the presence
of β-HB increases the synthesis of BDNF, a trophic factor which
mediates neuroprotection and is associated with cognitive improvement (Bredesen, 2017). Growing evidence of brain glucose hypometabolism in AD brains may provide a mechanism
to explain this correlation; namely that the abundance of ketone
bodies (KB) made available by a ketogenic diet may compensate
for the decreased glucose uptake in the brain by acting as a fuel
replacement, allowing the brain to work more efficiently.

Ketone Bodies and Brain Glucose Hypometabolism
The adult brain uses close to 23% of the body’s total energy
requirement, despite representing only about 2% of total body
weight, with glucose used as the predominant form of fuel. It is
well documented that glucose metabolism is significantly deteriorated in patients with AD. PET imaging has even shown significant
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hypometabolism in subjects with risk factors for AD prior to the
manifestation of any symptoms of cognitive decline. A recent review of several independent studies conducted on various groups
at risk for AD shows evidence of increased presymptomatic brain
glucose hypometabolism, ranging from 12-20% as compared to
the control, in all at-risk groups (Cunnane et al., 2016).
For instance, subjects who were homozygous for the E4 allele with a family history of AD, both risk factors for developing
AD, were screened for glucose hypometabolism against a control
group. Despite no difference in cognitive test results, the experimental group displayed decreased glucose metabolism in the
same brain regions identified in AD subjects, specifically in the
posterior cingulate and prefrontal, parietal, and temporal cortices
(Reiman et al., 2004). This indicates the possibility that PET scans
measuring the cerebral metabolic rate of glucose (CMRg) can
even be used to predict the onset of the disease.
Given the necessity of the brain for a constant energy supply,
Cunnane et al. has proposed that glucose hypometabolism in the
brain causes chronic, gradual brain energy starvation and may be
part of the disease etiology of AD. Thus, it seems reasonable for
potential therapeutic strategies to be aimed at correcting the
underlying problem of deteriorating brain fuel supply, specifically
by studying the body’s normal method of coping with decreased
glucose availability which occurs during fasting, malnutrition, or
strenuous exercise. When glucose supply is severely compromised, the brain uses ketone bodies, specifically β-hydroxybutyrate and acetoacetate, as the main reserve fuel (Owen et al., 1967).

Ketone vs Glucose Metabolism and Uptake
A study comparing brain glucose and ketone uptake was conducted to determine whether hypometabolism in the brain is
generalized to include both glucose and ketone metabolism or
a condition specific to glucose. Results showed that global brain
FDG (glucose analogue used in PET imaging) uptake was 14%
lower in early AD patients than the control group while no significant difference in C-Ac (acetoacetate analogue) uptake was
found. Thus, it seems possible that providing more KB to offset
the deficit in energy caused by glucose hypometabolism in aging
brains may decrease neuronal shrinkage and lower the risk of
developing AD. Indeed, clinical studies suggest that nutritional
treatments to increase plasma KB concentration may be effective against cognitive decline in early stages of AD (Cunnane et
al., 2016).
This theory has been tested in a cell culture model of AD with
positive results. Hippocampal cells of embryonic rats exposed
to Aβ42 demonstrated a 50% decrease in cell number. When
these cells were simultaneously exposed to β-HB, cell survival
doubled, indicating the potentially protective nature of β-HB
from amyloid toxicity (Henderson, 2008). The effectiveness of
ketone body treatment in human AD subjects has also been
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tested in clinical trial. In this study, subjects with mild to moderate probable AD consumed a beverage containing emulsified
medium-chain triglycerides (MCTs) to induce elevated serum
KB levels. Due to its shorter chain length, MCTs generate the
rapid production of ketone bodies, unlike longer fatty acid
chains. After 90 minutes, neurophyscological testing showed
a significant correlation between increased serum β-HB concentration and memory improvement, specifically for subjects
without the ApoE4 allele (Reger et. al, 2004).

The Ketoflex 12/3 Diet
Due to significant evidence indicating the positive effects of a
ketogenic state on cognitive function, the ReCODE Protocol
posits the need for a ketogenic nutritional plan, referred to as
the “Ketoflex 12/3” diet. The typical western diet is high in carbohydrates which inhibit ketogenesis and the utilization of KB.
A ketogenic diet promotes the release of free fatty acids to be
synthesized into KB, a process which is normally inhibited by
insulin signaling in the presence of carbohydrates.
The Keto in Ketoflex 12/3 refers to the induced state of
ketosis through a high-fat, low carbohydrate, plant-based diet.
Consumption of MCTs has also been shown to help induce
mild-ketosis and is recommended as well. These include coconut oil and palm kernel oil, of which approximately 10% consist
of these medium chain fatty acids, or MCT oil which is a concentrated form of the fraction of medium chain fatty acids in
coconut oil (Cunnane et al., 2016).
The flex in the Ketoflex 12/3 diet reflects the flexibility and
variety of food choices. The diet is mainly plant-based with
consumption of protein limited to just a few ounces a day. The
consumption of too much protein causes some of it to be converted to carbohydrates. In his book,The End of Alzheimer’s, Dr.
Bredesen outlines some specifics regarding food choices. These
include the following: choosing mainly foods with a glycemic
index lower than 35, as these foods do not require significant insulin release; eating detoxifying plants such as cilantro, cruciferous vegetables, kale, maca, and avocados to help eliminate toxins
such as heavy metals and Bisphenol A; and getting probiotics
and prebiotics either in pill form or from fermented foods such
as kimchi and sauerkraut, to help optimize bacteria in the gut.
He also recommends reducing cooking times and temperatures
to reduce the production of advanced glycation end products
which create inflammation, and optimizing nutrition with supplements such as reservatol, nicotinamide riboside, citricoline,
ubiquinol and polyquinoline quinine (Bredesen, 2017).
The 12/3 refers to the fasting times; namely a 12 hour fasting
period between the last meal at night and the first meal of the
next morning, and a 3 hour minimum between dinner and bedtime. As previously discussed, fasting is a highly effective way to
induce ketosis.
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Stress Management

Cognitive Training

There are several mechanisms that may account for the association of chronic unresolved stress with cognitive decline. Stress
activates the HPA axis to stimulate the release of stress related
hormones, such as cortisol, from the adrenal glands. Increased
levels of cortisol can lead to neuronal damage, particularly in
the hippocampus, thus contributing to cognitive and memory
decline. Stress also increases several risk factors for AD including blood glucose levels and hyperstimulation of neurons. Stress
is most closely linked with Type 3 Alzheimer’s, where onset of
cognitive decline often coincides with a stressor. Therefore, a
program for stress reduction is included in the ReCODE protocol, including meditation and yoga to lower cortisol levels and
prevent hippocampal atrophy (Bredesen, 2017)

Although the effects of brain exercises are controversial, cognitive training was one of the additional intervention elements
given to the intervention group of the FINGER study which
suggest a positive correlation between brain exercises and cognition (Ngandu et al., 2015).

Sleep Optimization
There are several neural mechanisms through which sleep affects cognition. Sleep is associated with reduced amyloid plaque
formation and induces autophagy in the brain, recycling dysfunctional components and improving cellular health. Production of
growth hormone increases during sleep allowing for cell repair
and production of supportive brain cells. More hours of sleep
allow for a longer period of fasting which helps improve insulin
sensitivity. ReCODE recommends at least 8 hours of sleep and
the use of melatonin if falling asleep is difficult (Bredesen, 2017).

Physical Activity
Exercise has been linked to many benefits related to cognition.
Among them are: reduced insulin resistance, increased ketosis,
stress reduction, improved sleep, and increased size of the hippocampus which is a key region in memory and shows atrophy
in AD. For optimal cognition benefits, ReCODE recommends
combining aerobic exercise with weight training 5 days a week
for 45 - 60 minutes per day (Bredesen, 2017).
Table 1. Summary of patients treated with the therapeutic system described

Patient Case Studies
The results of the multi-domain therapeutic system utilized by
Bredesen et al. on 10 patients is summarized in the table below.
As indicated, patients either reverted to their normal mental
status prior to exhibiting symptoms of cognitive impairment, or
showed improvement in cognition. One patient with advanced
AD, however, showed decline. These results suggest that memory loss in cases of Subjective Cognitive Impairment (SCI), Mild
Cognitive Impairment (MCI), and early AD may be reversed and
show sustained improvement using the therapeutic program
described by the ReCODE protocol (Bredesen, 2017).

Conclusion
Although preliminary results of this study seem promising, unlike the FINGER study, the results are only anecdotal and fail
to include predefined criteria for success, any indication as to
how patients were selected for inclusion, or clear descriptions
of the exact protocol followed for each patient. Additionally, the
protocol addresses many biomarkers that have been implicated
in AD without proving whether they are etiologically or epiphenomenally linked.There is also no control group for comparison.
Thus a more extensive, controlled clinical trial is required to determine the broad range effectiveness of the ReCODE protocol
on cognitive impairment.
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